<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes - Vrinten, C - 2014 | Cochrane Library</title> <meta content="Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes - Vrinten, C - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010028.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes - Vrinten, C - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010028.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010028.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes" name="citation_title"/> <meta content="Charlotte Vrinten" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Angeli M van der Zwaag" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="Stephanie S Weinreich" name="citation_author"/> <meta content="VU University Medical Center" name="citation_author_institution"/> <meta content="S.Weinreich@VUmc.nl" name="citation_author_email"/> <meta content="Rob JPM Scholten" name="citation_author"/> <meta content="Julius Center for Health Sciences and Primary Care / University Medical Center Utrecht" name="citation_author_institution"/> <meta content="Jan JGM Verschuuren" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010028.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/12/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010028.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010028.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010028.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic Agents [*therapeutic use]; Cholinesterase Inhibitors [therapeutic use]; Ephedrine [*therapeutic use]; Myasthenia Gravis [*drug therapy]; Myasthenia Gravis, Neonatal [drug therapy]; Myasthenic Syndromes, Congenital [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010028.pub2&amp;doi=10.1002/14651858.CD010028.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010028\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010028\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ja","ko","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010028.pub2",title:"Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes",firstPublishedDate:"Dec 17, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010028.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010028.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010028.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010028.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010028.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010028.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010028.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010028.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010028.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010028.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2188 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010028.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-sec-0059"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/appendices#CD010028-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#CD010028-cr-0002">Charlotte Vrinten</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#CD010028-cr-0003">Angeli M van der Zwaag</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#CD010028-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Stephanie S Weinreich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#CD010028-cr-0005">Rob JPM Scholten</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information#CD010028-cr-0006">Jan JGM Verschuuren</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information/en#CD010028-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 December 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010028.pub2">https://doi.org/10.1002/14651858.CD010028.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010028-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010028-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010028-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010028-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010028-abs-0002">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010028-abs-0007">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010028-abs-0001" lang="en"> <section id="CD010028-sec-0001"> <h3 class="title" id="CD010028-sec-0001">Background</h3> <p>Myasthenia is a condition in which neuromuscular transmission is affected by antibodies against neuromuscular junction components (autoimmune myasthenia gravis, MG; and neonatal myasthenia gravis, NMG) or by defects in genes for neuromuscular junction proteins (congenital myasthenic syndromes, CMSs). Clinically, some individuals seem to benefit from treatment with ephedrine, but its effects and adverse effects have not been systematically evaluated. </p> </section> <section id="CD010028-sec-0002"> <h3 class="title" id="CD010028-sec-0002">Objectives</h3> <p>To assess the effects and adverse effects of ephedrine in people with autoimmune MG, transient neonatal MG, and the congenital myasthenic syndromes. </p> </section> <section id="CD010028-sec-0003"> <h3 class="title" id="CD010028-sec-0003">Search methods</h3> <p>On 17 November 2014, we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE. We also searched reference lists of articles, conference proceedings of relevant conferences, and prospective trial registers. In addition, we contacted manufacturers and researchers in the field. </p> </section> <section id="CD010028-sec-0004"> <h3 class="title" id="CD010028-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) and quasi‐RCTs comparing ephedrine as a single or add‐on treatment with any other active treatment, placebo, or no treatment in adults or children with autoimmune MG, NMG, or CMSs. </p> </section> <section id="CD010028-sec-0005"> <h3 class="title" id="CD010028-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed study design and quality, and extracted data. We contacted study authors for additional information. We collected information on adverse effects from included articles, and contacted authors. </p> </section> <section id="CD010028-sec-0006"> <h3 class="title" id="CD010028-sec-0006">Main results</h3> <p>We found no RCTs or quasi‐RCTs, and therefore could not establish the effect of ephedrine on MG, NMG and CMSs. We describe the results of 53 non‐randomised studies narratively in the Discussion section, including observations of endurance, muscle strength and quality of life. Effects may differ depending on the type of myasthenia. Thirty‐seven studies were in participants with CMS, five in participants with MG, and in 11 the precise form of myasthenia was unknown. We found no studies for NMG. Reported adverse effects included tachycardia, sleep disturbances, nervousness, and withdrawal symptoms. </p> </section> <section id="CD010028-sec-0007"> <h3 class="title" id="CD010028-sec-0007">Authors' conclusions</h3> <p>There was no evidence available from RCTs or quasi‐RCTs, but some observations from non‐randomised studies are available. There is a need for more evidence from suitable forms of prospective RCTs, such as series of n‐of‐one RCTs, that use appropriate and validated outcome measures. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010028-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010028-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010028-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010028-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010028-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010028-abs-0008">한국어</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010028-abs-0004" lang="en"> <h3>Ephedrine treatment for myasthenia gravis, neonatal myasthenia and congenital myasthenic syndromes </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of ephedrine in adults and children with myasthenia gravis (MG), neonatal myasthenia and the congenital myasthenic syndromes (CMSs). </p> <p><b>Background</b> </p> <p>Myasthenia is a group of rare conditions in which muscle fatigue and weakness are the main symptoms. These symptoms occur because signals do not pass from the nerve to the muscle properly. In autoimmune MG and neonatal myasthenia, the person’s own immune system attacks the proteins that carry these signals. In CMS, there are inborn defects in these proteins. Most people with myasthenia respond well to standard drug and supportive treatments. Ephedrine could have a role when initial treatment is not successful. Ephedrine is a stimulating drug, although exactly how it works is unknown. As far as we know, the use of ephedrine has never been properly assessed in people with myasthenia. </p> <p><b>Key results and quality of the evidence</b> </p> <p>Randomised studies provide the best quality evidence. We did not find any randomised studies of ephedrine in neonatal myasthenia, autoimmune MG, or the CMSs. Fifty‐three non‐randomised studies, which provide weaker evidence than randomised studies, have reported the effects of ephedrine on muscle weakness, fatigue, and quality of life. We have described these findings narratively in the Discussion section of the review. Effects may differ depending on the type of myasthenia. Adverse effects that were reported in these studies included palpitations, sleep disturbances, nervousness, and irritability when ephedrine was stopped. We conclude that there is a need for high‐quality studies to assess the effects of ephedrine in MG, neonatal myasthenia, and the CMSs. </p> <p>The evidence is current to November 2014.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010028-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010028-sec-0087"></div> <h3 class="title" id="CD010028-sec-0088">Implications for practice</h3> <section id="CD010028-sec-0088"> <p>No randomised controlled trials or quasi‐randomised controlled trials have been conducted to determine the effects of ephedrine in myasthenia gravis, neonatal myasthenia gravis, or congenital myasthenic syndromes. Our search did not identify any non‐randomised studies which described the effect of ephedrine in neonatal myasthenia gravis. Limited evidence is available from before‐and‐after studies, case series, and case reports, and suggests that there might be an effect of ephedrine on endurance, muscle strength, and quality of life in people with myasthenia gravis and some types of congenital myasthenic syndrome. Effects may depend on the type of myasthenia, however, and use of ephedrine may be limited by adverse effects such as tachycardia, sleep disturbances, nervousness, habituation effects, and withdrawal symptoms. Due to the high risk of bias, the results of these non‐randomised studies should be interpreted with care. </p> </section> <h3 class="title" id="CD010028-sec-0089">Implications for research</h3> <section id="CD010028-sec-0089"> <p>In order to obtain valid and reliable estimates of the effects of ephedrine on myasthenic symptoms, it is necessary that prospective, blinded, randomised and controlled trials are conducted for the different types of myasthenia described in this review. Due to the rarity of many of the congenital myasthenic syndromes and the small numbers of people with myasthenia gravis who respond poorly to standard therapy and for whom treatment with ephedrine may thus be considered, it may prove unfeasible to conduct parallel group‐randomised controlled trials, even on an international scale. Other types of randomised controlled trial should therefore be considered, such as randomised controlled cross‐over trials or (series of) n‐of‐one randomised controlled trials. Moreover, more research is needed to establish which outcome measures should be used to determine the effects of treatment. Some studies included in this review (e.g. <a href="./references#CD010028-bbs2-0046" title="FeliceK , RelvaG . Ephedrine in the treatment of congenital myasthenic syndrome. Muscle &amp; Nerve1996; Vol. 19, issue 6:799‐800. ">Felice 1996</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>; <a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>) described discrepancies between objective measures, such as forced vital capacity and electromyographic studies, and subjective measures of treatment effect, such as self‐reported quality of life. This suggests that the objective outcome measures chosen in those studies may not have been optimal for recording any improvements in myasthenic symptoms, or alternatively that the experienced beneficial effects of ephedrine may reflect an underlying placebo effect. Furthermore, more research is needed to establish the best time interval at which the outcomes should be measured. Some people with autoimmune myasthenia gravis or congenital myasthenic syndromes seem to respond to treatment with ephedrine within minutes or days (<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>; <a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>), but several authors have commented that it may take weeks or months for ephedrine to reach full effect (<a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0105" title="RobbSA , MuntoniF , SimondsAK . Respiratory management of congenital myasthenic syndromes in childhood: Workshop 8th December 2009, UCL Institute of Neurology, London, UK. Neuromuscular Disorders2010;20(12):833‐8. ">Robb 2010</a>). Thus, the time interval for the outcome measures may need to be changed in future reviews to reflect these observations. It should be noted, however, that conducting trials to establish the efficacy of ephedrine may be hampered by the issues around the availability of ephedrine, as outlined in the <a href="#CD010028-sec-0029">Background</a>. </p> <p>Blind, randomised, controlled studies of adequate duration and using well‐chosen and standardised outcomes measured at appropriate intervals may help to establish the true effect of ephedrine on myasthenic symptoms for the different types of myasthenia. The search for valid and reliable estimates of the effect of ephedrine on myasthenic symptoms could be greatly facilitated by setting up an international database that allows all people with myasthenia who are treated with ephedrine to be registered and tracked over time. Such a register should include those people who did and did not benefit from ephedrine, those in whom it was discontinued (and why), and those who experienced adverse effects of ephedrine. </p> <p>In summary, the studies included in this review suggest that ephedrine may improve muscle weakness and fatigue in some people with myasthenia gravis and in some types of congenital myasthenic syndrome, but scientifically sound and novel ways to validly and reliably estimate the effect of ephedrine in these rare conditions are needed. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010028-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010028-sec-0029"></div> <section id="CD010028-sec-0030"> <h3 class="title" id="CD010028-sec-0030">Description of the condition</h3> <p>Myasthenia is a condition in which neuromuscular transmission is affected due either to antibodies against neuromuscular junction components (myasthenia gravis and neonatal myasthenia gravis), or to defects in any of the various genes that encode for neuromuscular junction proteins (congenital myasthenic syndromes, CMSs). The antibody‐mediated form can be subdivided into autoimmune (childhood or adult onset) myasthenia gravis (MG), and transient neonatal myasthenia gravis (NMG), which is caused by a passive transfer of antibodies from a mother with autoimmune MG to her child. In this review, we considered treatment with ephedrine for all of these types of myasthenia. Each type is briefly described in the following paragraphs. </p> <section id="CD010028-sec-0031"> <h4 class="title">Autoimmune myasthenia gravis</h4> <p>Autoimmune MG is a rare disorder with a prevalence of 60 to 200 per million and an annual incidence of four to six per million (<a href="./references#CD010028-bbs2-0062" title="JuelVC , MasseyJM . Myasthenia gravis. Orphanet Journal of Rare Diseases2007;2(Nov):44‐57. ">Juel 2007</a>; <a href="./references#CD010028-bbs2-0084" title="MeyerA , LevyY . Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmunity Reviews2010;9(5):A383‐6. ">Meyer 2010</a>; <a href="./references#CD010028-bbs2-0129" title="WirtzPW , NijnuisMG , SotodehM , WilliamsLN , BrahimJJ , PutterH , et al. The epidemiology of myasthenia gravis, Lambert‐Eaton myasthenic syndrome and their associated tumours in th northern part of the province of South Holland. Journal of Neurology2003;250(6):698‐701. ">Wirtz 2003</a>). Eighty to 90 per cent of people with autoimmune MG produce autoantibodies directed against the acetylcholine receptor of the motor endplate (AChR MG) (<a href="./references#CD010028-bbs2-0063" title="KeeseyJC . Clinical evaluation and management of myasthenia gravis. Muscle &amp; Nerve2004;29(4):484‐505. ">Keesey 2004</a>; <a href="./references#CD010028-bbs2-0084" title="MeyerA , LevyY . Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmunity Reviews2010;9(5):A383‐6. ">Meyer 2010</a>). About five per cent of those with autoimmune MG have autoantibodies directed against the muscle‐specific tyrosine kinase receptor of the motor endplate (MuSK MG) (<a href="./references#CD010028-bbs2-0029" title="DrachmanDB . Myasthenia gravis. New England Journal of Medicine1994;330(25):1797‐810. ">Drachman 1994</a>; <a href="./references#CD010028-bbs2-0059" title="HochW , McConvilleJ , HelmsS , Newsom‐DavisJ , MelmsA , VincentA . Auto‐antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine2001;7(3):365‐8. ">Hoch 2001</a>; <a href="./references#CD010028-bbs2-0123" title="VincentA , McConvilleJ , FarrugiaME , BowenJ , PlestedP , TangT , et al. Antibodies in myasthenia gravis and related disorders. Annals of the New York Academy of Sciences2003 Sep;998:324‐35. ">Vincent 2003</a>). Finally, some people have autoantibodies against Lrp4 (<a href="./references#CD010028-bbs2-0058" title="HiguchiO , HamuroJ , MotomuraM , YamanashiY . Autoantibodies to low‐density lipoprotein receptor‐related protein 4 in myasthenia gravis. Annals of Neurology2011;69(2):418‐22. ">Higuchi 2011</a>; <a href="./references#CD010028-bbs2-0101" title="PevznerA , SchoserB , PetersK , CosmaNC , KarakatsaniA , SchalkeB , et al. Anti‐LRP4 autoantibodies in AChR‐ and MuSK‐antibody negative myasthenia gravis. Journal of Neurology2012;259(3):427‐35. ">Pevzner 2012</a>; <a href="./references#CD010028-bbs2-0134" title="ZhangB , TzartosJS , BelimeziM , RaghebS , BealmearB , LewisRA , et al. Autoantibodies to lipoprotein‐related protein 4 in patients with double‐seronegative myasthenia gravis. Archives of Neurology2012;69(4):445‐51. ">Zhang 2012</a>). These are considered 'seropositive' for AChR, MuSK, or Lrp4 antibodies. A minority of those affected are seronegative; they lack antibodies against AChR or MuSK as measured by standard assays. However, in seronegative people, low titre antibodies to <i>clustered</i> acetylcholine receptors can sometimes be detected using cell‐based assays (<a href="./references#CD010028-bbs2-0071" title="LeiteMI , JacobS , ViegasS , CossinsJ , CloverL , MorganBP , et al. IgGI antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain2008;131(7):1940‐52. ">Leite 2008</a>). Ten to 15 per cent of people with AChR MG have underlying thymoma (<a href="./references#CD010028-bbs2-0063" title="KeeseyJC . Clinical evaluation and management of myasthenia gravis. Muscle &amp; Nerve2004;29(4):484‐505. ">Keesey 2004</a>; <a href="./references#CD010028-bbs2-0129" title="WirtzPW , NijnuisMG , SotodehM , WilliamsLN , BrahimJJ , PutterH , et al. The epidemiology of myasthenia gravis, Lambert‐Eaton myasthenic syndrome and their associated tumours in th northern part of the province of South Holland. Journal of Neurology2003;250(6):698‐701. ">Wirtz 2003</a>). Symptoms of autoimmune MG include muscle fatigability and fluctuating muscle weakness in cranial and skeletal muscles. Therapy consists of treatment with an acetylcholinesterase inhibitor (AChEI), or immunosuppressive or immunomodulatory treatment to diminish the effect of the autoantibodies. Surgical treatment for autoimmune MG consists of thymectomy. The benefits of this procedure in people with non‐thymoma MG have not been established conclusively (<a href="./references#CD010028-bbs2-0062" title="JuelVC , MasseyJM . Myasthenia gravis. Orphanet Journal of Rare Diseases2007;2(Nov):44‐57. ">Juel 2007</a>; <a href="./references#CD010028-bbs2-0063" title="KeeseyJC . Clinical evaluation and management of myasthenia gravis. Muscle &amp; Nerve2004;29(4):484‐505. ">Keesey 2004</a>; <a href="./references#CD010028-bbs2-0084" title="MeyerA , LevyY . Chapter 33: Geoepidemiology of myasthenia gravis. Autoimmunity Reviews2010;9(5):A383‐6. ">Meyer 2010</a>). An international trial is ongoing (<a href="./references#CD010028-bbs2-0091" title="NCT00294658 . A multi‐center, single‐blind, randomized study comparing thymectomy to no thymectomy in non‐thymomatous myasthenia gravis (MG) patients receiving prednisone. clinicaltrials.gov/show/NCT00294658 (accessed 29 September 2013). ">NCT00294658</a>) and a published Cochrane systematic review on thymectomy for non‐thymomatous myasthenia gravis will be updated once this evidence is available (<a href="./references#CD010028-bbs2-0018" title="CeaG , BenatarM , VerdugoRJ , SalinasRA . Thymectomy for non‐thymomatous myasthenia gravis. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD008111.pub2] ">Cea 2013</a>). Treatment of autoimmune MG with AChEIs (<a href="./references#CD010028-bbs2-0083" title="MehndirattaMM , PandeyS , KuntzerT . Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD006986.pub3] ">Mehndiratta 2014</a>), corticosteroids (<a href="./references#CD010028-bbs2-0112" title="Schneider‐GoldC , GajdosP , ToykaKV , HohlfeldRR . Corticosteroids for myasthenia gravis. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002828.pub2] ">Schneider‐Gold 2005</a>), immunosuppressive agents (<a href="./references#CD010028-bbs2-0054" title="HartIK , SathasivamS , SharsharT . Immunosuppressive agents for myasthenia gravis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005224.pub2] ">Hart 2007</a>), intravenous immunoglobulin (IVIg) (<a href="./references#CD010028-bbs2-0048" title="GajdosP , ChevretS , ToykaKV . Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD002277.pub4] ">Gajdos 2012</a>) and plasma exchange (<a href="./references#CD010028-bbs2-0047" title="GajdosP , ChevretS , ToykaKV . Plasma exchange for generalised myasthenia gravis. Cochrane Database of Systematic Reviews2002, Issue 4. [DOI: 10.1002/14651858.CD002275] ">Gajdos 2002</a>) have been reviewed elsewhere. </p> </section> <section id="CD010028-sec-0032"> <h4 class="title">(Transient) neonatal myasthenia gravis</h4> <p>Transient neonatal myasthenia gravis (NMG) is caused by maternal autoantibodies that are passively transferred from a mother with autoimmune MG to her child. Neonatal myasthenia gravis occurs in 10% to 20% of the newborns of mothers with autoimmune MG (<a href="./references#CD010028-bbs2-0028" title="DjelmisJ , SostarkoM , MayerD , IvanisevicM . Myasthenia gravis in pregnancy: report on 69 cases. European Journal of Obstetrics Gynecology and Reproductive Biology2002;104(1):21‐5. ">Djelmis 2002</a>; <a href="./references#CD010028-bbs2-0043" title="EvoliA . Acquired myasthenia gravis in childhood. Current Opinion in Neurology2010;23(5):536‐40. ">Evoli 2010</a>). The annual incidence is unknown (<a href="./references#CD010028-bbs2-0098" title="PapazianO . Transient neonatal myasthenia gravis. Journal of Child Neurology1992;7(2):135‐41. ">Papazian 1992</a>). Symptoms usually begin several hours after birth and include hypotonia and weakness, resulting in respiratory distress, poor suck and cry, and difficulty swallowing (<a href="./references#CD010028-bbs2-0028" title="DjelmisJ , SostarkoM , MayerD , IvanisevicM . Myasthenia gravis in pregnancy: report on 69 cases. European Journal of Obstetrics Gynecology and Reproductive Biology2002;104(1):21‐5. ">Djelmis 2002</a>; <a href="./references#CD010028-bbs2-0043" title="EvoliA . Acquired myasthenia gravis in childhood. Current Opinion in Neurology2010;23(5):536‐40. ">Evoli 2010</a>). More severe cases present with foetal polyhydramnios (excess of amniotic fluid in the amniotic sac) and congenital arthrogryposis multiplex (congenital contractures of multiple joints), followed by hypotonia and weakness (<a href="./references#CD010028-bbs2-0021" title="ChiezaJT , FlemingI , ParryN , SkeltonVA . Maternal myasthenia gravis complicated by fetal arthrogryposis multiplex congenita. International Journal of Obstetric Anesthesia2011;20(1):79‐82. ">Chieza 2011</a>; <a href="./references#CD010028-bbs2-0043" title="EvoliA . Acquired myasthenia gravis in childhood. Current Opinion in Neurology2010;23(5):536‐40. ">Evoli 2010</a>; <a href="./references#CD010028-bbs2-0067" title="KlehmetJ , DudenhausenJ , MeiselA . Course and treatment of myasthenia gravis during pregnancy [Verlauf und Behandlung der Myasthenia gravis in der Schwangerschaft]. Nervenarzt2010;81(8):956‐62. ">Klehmet 2010</a>; <a href="./references#CD010028-bbs2-0098" title="PapazianO . Transient neonatal myasthenia gravis. Journal of Child Neurology1992;7(2):135‐41. ">Papazian 1992</a>; <a href="./references#CD010028-bbs2-0102" title="PlauchéWC . Myasthenia gravis in mothers and their newborns. Clinical Obstetrics and Gynecology1991;34(1):82‐99. ">Plauché 1991</a>). Treatment is supportive and usually consists of AChEIs, small frequent feedings and respiratory support, if necessary (<a href="./references#CD010028-bbs2-0098" title="PapazianO . Transient neonatal myasthenia gravis. Journal of Child Neurology1992;7(2):135‐41. ">Papazian 1992</a>; <a href="./references#CD010028-bbs2-0102" title="PlauchéWC . Myasthenia gravis in mothers and their newborns. Clinical Obstetrics and Gynecology1991;34(1):82‐99. ">Plauché 1991</a>). Ninety per cent of affected newborns recover completely within weeks to months. Permanent symptoms have only been reported in rare cases (<a href="./references#CD010028-bbs2-0098" title="PapazianO . Transient neonatal myasthenia gravis. Journal of Child Neurology1992;7(2):135‐41. ">Papazian 1992</a>). </p> </section> <section id="CD010028-sec-0033"> <h4 class="title">Congenital myasthenic syndromes</h4> <p>The congenital myasthenic syndromes (CMSs) are a heterogeneous group of diseases caused by mutations in genes that encode for proteins that are essential in neuromuscular transmission. The combined prevalence of CMSs is one to two people per 500,000 (<a href="./references#CD010028-bbs2-0044" title="EymardB . Congenital myasthenic syndromes. www.orpha.net 2007 (accessed 3 December 2014). ">Eymard 2007</a>). The syndromes can be divided into three subclasses: presynaptic, synaptic and post‐synaptic, according to where in the neuromuscular junction the mutated gene is expressed (<a href="./references#CD010028-bbs2-0006" title="BarišićN , ChaouchA , MüllerJS , LochmüllerH . Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. European Journal of Paediatric Neurology2011;15(3):189‐96. ">Barišić 2011</a>; <a href="./references#CD010028-bbs2-0039" title="EngelAG . Current status of the congenital myasthenic syndromes. Neuromuscular Disorders2012;22(2):99‐111. ">Engel 2012</a>). Mutations are known in roughly 50% to 70% of those diagnosed with CMS (<a href="./references#CD010028-bbs2-0044" title="EymardB . Congenital myasthenic syndromes. www.orpha.net 2007 (accessed 3 December 2014). ">Eymard 2007</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>). Symptoms include fatigability and weakness of limb‐girdle muscles, and weakness of ocular, facial and bulbar muscles (<a href="./references#CD010028-bbs2-0002" title="AbichtA , LochmüllerH . Congenital Myasthenic Syndromes. GeneReviews at Gene Tests: Medical Genetics Information Resource (database online). Seattle: University of Washington. Available at www.ncbi.nlm.nih.gov/books/NBK1168/, 1993 ‐ 2014. Last revision: June 28, 2012 (accessed 3 December 2014). ">Abicht 2003</a>; <a href="./references#CD010028-bbs2-0044" title="EymardB . Congenital myasthenic syndromes. www.orpha.net 2007 (accessed 3 December 2014). ">Eymard 2007</a>; <a href="./references#CD010028-bbs2-0109" title="ScharaU , LochmüllerH . Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics2008;5(4):542‐7. ">Schara 2008</a>). Respiratory difficulty may be present in severe cases (<a href="./references#CD010028-bbs2-0002" title="AbichtA , LochmüllerH . Congenital Myasthenic Syndromes. GeneReviews at Gene Tests: Medical Genetics Information Resource (database online). Seattle: University of Washington. Available at www.ncbi.nlm.nih.gov/books/NBK1168/, 1993 ‐ 2014. Last revision: June 28, 2012 (accessed 3 December 2014). ">Abicht 2003</a>; <a href="./references#CD010028-bbs2-0006" title="BarišićN , ChaouchA , MüllerJS , LochmüllerH . Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. European Journal of Paediatric Neurology2011;15(3):189‐96. ">Barišić 2011</a>). Foetal manifestations include arthrogryposis multiplex congenita and polyhydramnios (<a href="./references#CD010028-bbs2-0044" title="EymardB . Congenital myasthenic syndromes. www.orpha.net 2007 (accessed 3 December 2014). ">Eymard 2007</a>). The first symptoms, if not present at birth, usually appear within the first year of life, but sometimes at a later age, or even in adulthood (<a href="./references#CD010028-bbs2-0044" title="EymardB . Congenital myasthenic syndromes. www.orpha.net 2007 (accessed 3 December 2014). ">Eymard 2007</a>; <a href="./references#CD010028-bbs2-0096" title="PalaceJ , BeesonD . The congenital myasthenic syndromes. Journal of Neuroimmunology2008;201‐202:2‐5. ">Palace 2008</a>). The diagnosis is based on familial occurrence, clinical findings, early onset, and on determining the specific type of syndrome. This can be done using electromyography, the response to AChEIs, studies of muscle endplate morphology, and molecular genetic testing (<a href="./references#CD010028-bbs2-0002" title="AbichtA , LochmüllerH . Congenital Myasthenic Syndromes. GeneReviews at Gene Tests: Medical Genetics Information Resource (database online). Seattle: University of Washington. Available at www.ncbi.nlm.nih.gov/books/NBK1168/, 1993 ‐ 2014. Last revision: June 28, 2012 (accessed 3 December 2014). ">Abicht 2003</a>; <a href="./references#CD010028-bbs2-0044" title="EymardB . Congenital myasthenic syndromes. www.orpha.net 2007 (accessed 3 December 2014). ">Eymard 2007</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>). In contrast to autoimmune MG, CMSs are not due to autoantibodies, and immunomodulating therapies are therefore not effective. Pharmacological treatment of the CMS varies by syndrome, but usually consists of an AChEI, 3,4‐diaminopyridine (3,4‐DAP), ephedrine, albuterol, or a combination of these (<a href="./references#CD010028-bbs2-0006" title="BarišićN , ChaouchA , MüllerJS , LochmüllerH . Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. European Journal of Paediatric Neurology2011;15(3):189‐96. ">Barišić 2011</a>; <a href="./references#CD010028-bbs2-0072" title="LiewluckT , SelcenD , EngelAG . Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and DOK‐7 myasthenia. Muscle &amp; Nerve2011;44(5):789‐94. ">Liewluck 2011</a>; <a href="./references#CD010028-bbs2-0106" title="SadehM , ShenX , EngelAG . Beneficial effects of albuterol in congenital myasthenic syndrome with epsilon‐subunit mutations. Muscle &amp; Nerve2011;44(2):289‐91. ">Sadeh 2011</a>; <a href="./references#CD010028-bbs2-0109" title="ScharaU , LochmüllerH . Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics2008;5(4):542‐7. ">Schara 2008</a>). Non‐pharmacological treatments include physiotherapy, gastric tube for feeding (if needed), close monitoring of respiratory and bulbar functions and, when necessary, respiratory support. Genetic counselling and prenatal diagnosis may also be warranted (<a href="./references#CD010028-bbs2-0006" title="BarišićN , ChaouchA , MüllerJS , LochmüllerH . Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. European Journal of Paediatric Neurology2011;15(3):189‐96. ">Barišić 2011</a>; <a href="./references#CD010028-bbs2-0109" title="ScharaU , LochmüllerH . Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics2008;5(4):542‐7. ">Schara 2008</a>). The prognosis is variable and for most CMS subtypes, cases ranging from mild to severe have been reported (<a href="./references#CD010028-bbs2-0109" title="ScharaU , LochmüllerH . Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics2008;5(4):542‐7. ">Schara 2008</a>). </p> </section> </section> <section id="CD010028-sec-0034"> <h3 class="title" id="CD010028-sec-0034">Description of the intervention</h3> <p>The initial treatment for people with most forms of myasthenia consists of AChEIs or 3,4‐DAP, or both. Some who do not respond well to these treatments seem to benefit from (add‐on) treatment with ephedrine, for example, those with certain CMSs (<a href="./references#CD010028-bbs2-0037" title="EngelAG . The therapy of congenital myasthenic syndromes. Neurotherapeutics2007;4(2):252‐7. ">Engel 2007</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>). Ephedrine as a sulphate tablet is generally taken orally. Typical doses in adults are 25 mg twice daily. The dosage for children is 0.5 to 3 mg/kg/day divided over several doses, but doses of 150 to 200 mg per day are sometimes necessary (<a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>; <a href="./references#CD010028-bbs2-0037" title="EngelAG . The therapy of congenital myasthenic syndromes. Neurotherapeutics2007;4(2):252‐7. ">Engel 2007</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>). Ephedrine is rapidly absorbed. It is partially metabolised to norephedrine in the liver, but is mainly excreted in the urine unchanged (<a href="./references#CD010028-bbs2-0024" title="CsajkaC , HallerCA , BenowitzNL , VerottaD . Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. British Journal of Clinical Pharmacology2005;59(3):335‐45. ">Csajka 2005</a>). The renal clearance is dependent on urine pH. Mean plasma half‐life is approximately six hours and ranges from three to 11 hours (<a href="./references#CD010028-bbs2-0024" title="CsajkaC , HallerCA , BenowitzNL , VerottaD . Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. British Journal of Clinical Pharmacology2005;59(3):335‐45. ">Csajka 2005</a>; <a href="./references#CD010028-bbs2-0131" title="Electronic MedicinesCompendium . Summary of product characteristics ephedrine hydrochloride 15, 30 &amp; 60 mg tablets (Wockhardt UK Ltd). Electronic Medicines Compendium. Datapharm Communications Ltd Last update: 21/11/2008. Available from www.medicines.org.uk/EMC/ (accessed 3 December 2014). ">Wockhardt 2008</a>). The most common side effects are tachycardia (rapid heart rate), anxiety, nausea, restlessness and insomnia. In children, ephedrine may stimulate nocturnal enuresis, sleeplessness, or sometimes sedation (<a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>; <a href="./references#CD010028-bbs2-0131" title="Electronic MedicinesCompendium . Summary of product characteristics ephedrine hydrochloride 15, 30 &amp; 60 mg tablets (Wockhardt UK Ltd). Electronic Medicines Compendium. Datapharm Communications Ltd Last update: 21/11/2008. Available from www.medicines.org.uk/EMC/ (accessed 3 December 2014). ">Wockhardt 2008</a>). Contraindications for ephedrine are renal insufficiency, hypertension and certain cardiac diseases, such as long QT syndrome and angina pectoris (<a href="./references#CD010028-bbs2-0024" title="CsajkaC , HallerCA , BenowitzNL , VerottaD . Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. British Journal of Clinical Pharmacology2005;59(3):335‐45. ">Csajka 2005</a>; <a href="./references#CD010028-bbs2-0131" title="Electronic MedicinesCompendium . Summary of product characteristics ephedrine hydrochloride 15, 30 &amp; 60 mg tablets (Wockhardt UK Ltd). Electronic Medicines Compendium. Datapharm Communications Ltd Last update: 21/11/2008. Available from www.medicines.org.uk/EMC/ (accessed 3 December 2014). ">Wockhardt 2008</a>). Unlike AChEIs or 3,4‐DAP, there are currently no indications that ephedrine may worsen symptoms in certain subtypes of the CMS (<a href="./references#CD010028-bbs2-0006" title="BarišićN , ChaouchA , MüllerJS , LochmüllerH . Genetic heterogeneity and pathophysiological mechanisms in congenital myasthenic syndromes. European Journal of Paediatric Neurology2011;15(3):189‐96. ">Barišić 2011</a>). </p> </section> <section id="CD010028-sec-0035"> <h3 class="title" id="CD010028-sec-0035">How the intervention might work</h3> <p>Ephedrine is a sympathomimetic agent which mainly affects the adrenergic receptors (<a href="./references#CD010028-bbs2-0131" title="Electronic MedicinesCompendium . Summary of product characteristics ephedrine hydrochloride 15, 30 &amp; 60 mg tablets (Wockhardt UK Ltd). Electronic Medicines Compendium. Datapharm Communications Ltd Last update: 21/11/2008. Available from www.medicines.org.uk/EMC/ (accessed 3 December 2014). ">Wockhardt 2008</a>). Its beneficial effects in people with autoimmune MG have long been recognised (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>; <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a>; <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a>). However, treatment with ephedrine has fallen into disuse after reports appeared of an increased risk of adverse cardiovascular and central nervous system events (stroke) associated with dietary supplements containing ephedra alkaloids, such as ephedrine and pseudoephedrine, and appetite suppressants containing norephedrine or phenylpropanolamine (<a href="./references#CD010028-bbs2-0051" title="HallerCA , BenowitzNL . Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. New England Journal of Medicine2000;343(25):1833‐8. ">Haller 2000</a>; <a href="./references#CD010028-bbs2-0064" title="KernanWN , ViscoliCM , BrassLM , BroderickJP , BrottT , FeldmannE , et al. Phenylpropanolamine and the risk of hemorrhagic stroke. New England Journal of Medicine2000;343(25):1826‐32. ">Kernan 2000</a>). It has never been conclusively established that this is also the case for pharmaceutical preparations containing only ephedrine in doses used in the treatment of MG or any other registered indication for ephedrine‐containing products (<a href="./references#CD010028-bbs2-0042" title="ErnstME , HartzA . Phenylpropanolamine and hemorrhagic stroke. New England Journal of Medicine2001; Vol. 344, issue 14:1094‐5. ">Ernst 2001</a>). Recently, interest has increased in ephedrine as treatment for CMS, particularly <i>DOK7</i> CMS (<a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>;<a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>;<a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a>). Its mechanism of action in MG has been investigated (<a href="./references#CD010028-bbs2-0049" title="GallagherJP , Shinnick‐GallagherP . Ephedrine and neuromuscular transmission, in vivo. Neuropharmacology1979;18(10):749‐54. ">Gallagher 1979</a>; <a href="./references#CD010028-bbs2-0090" title="MiloneM , EngelAG . Block of the endplate acetylcholine receptor channel by the sympathomimetic agents ephedrine, pseudoephedrine and albuterol. Brain Research1996;740(1‐2):346‐52. ">Milone 1996</a>; <a href="./references#CD010028-bbs2-0115" title="Shinnick‐GallagherP , GallagherJP . Ephedrine: a postsynaptic depressant drug at the mammalian neuromuscular junction. Neuropharmacology1979;18(10):755‐61. ">Shinnick‐Gallagher 1979</a>; <a href="./references#CD010028-bbs2-0116" title="SiebJP , EngelAG . Ephedrine: effects on neuromuscular transmission. Brain Research1993;623(1):167‐71. ">Sieb 1993</a>), but is not well understood (<a href="./references#CD010028-bbs2-0037" title="EngelAG . The therapy of congenital myasthenic syndromes. Neurotherapeutics2007;4(2):252‐7. ">Engel 2007</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>). For example, Sieb and Engel measured the effects of different concentrations of ephedrine on the muscle endplate in an in vitro canine model using microelectrode techniques. Ephedrine increased the quantal content of the endplate potential as well as the probability of quantal release, but at concentrations that would not be reached in those treated (<a href="./references#CD010028-bbs2-0116" title="SiebJP , EngelAG . Ephedrine: effects on neuromuscular transmission. Brain Research1993;623(1):167‐71. ">Sieb 1993</a>). Ephedrine might improve muscular transmission by stimulating β2‐adrenergic receptors, as well as by partially stabilising the structure of the neuromuscular junction (<a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>). </p> </section> <section id="CD010028-sec-0036"> <h3 class="title" id="CD010028-sec-0036">Why it is important to do this review</h3> <p>Ephedrine is a drug that is only used by a small number of people with myasthenia. Clinically, these people seem to benefit from this drug (<a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>). However, its cost is not always reimbursed by health insurance companies due to a perceived lack of scientific evidence for efficacy. Furthermore, ephedrine is a methamphetamine analogue and can be used as a precursor in the (illegal) production of methamphetamine (<a href="./references#CD010028-bbs2-0085" title="Medicines and Healthcare products Regulatory Agency (MHRA). Pseudoephedrine‐ and ephedrine‐containing medicines: 2012 review of actions to manage the risk of misuse. Available from www.mhra.gov.uk 2012 Oct (accessed 3 December 2014). ">MHRA 2012</a>; <a href="./references#CD010028-bbs2-0121" title="United Nations Office on Drugs and Crime. United Nations convention against illicit traffic in narcotic drugs and psychotropic substances, 1988. Available from www.unodc.org (accessed 3 December 2014). ">UNODC 1988</a>). It has been registered as a precursor drug in the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (<a href="./references#CD010028-bbs2-0121" title="United Nations Office on Drugs and Crime. United Nations convention against illicit traffic in narcotic drugs and psychotropic substances, 1988. Available from www.unodc.org (accessed 3 December 2014). ">UNODC 1988</a>). Thus, the import and distribution of ephedrine is strictly regulated, which can jeopardise its availability for medicinal use (<a href="./references#CD010028-bbs2-0026" title="Drug EnforcementAdministration , U.S. Department of Justice. Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Federal Register. Document number: 2010‐1968. 2010 Feb. Available from www.federalregister.gov (accessed 3 December 2014). [RIN 1117‐AB09] ">DEA 2010</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>; <a href="./references#CD010028-bbs2-0121" title="United Nations Office on Drugs and Crime. United Nations convention against illicit traffic in narcotic drugs and psychotropic substances, 1988. Available from www.unodc.org (accessed 3 December 2014). ">UNODC 1988</a>). This is especially true for people with myasthenia, because it is not a registered indication. For example, no ephedrine preparation is currently registered for marketing approval in humans in the European Union (EU) (<a href="./references#CD010028-bbs2-0035" title="European Medicines Agency. European Public Assessment Report database. Available from: www.ema.europa.eu (accessed 3 December 2014). ">EMA 2014</a>), and pharmacies must either import the tablets from outside the EU or prepare the ephedrine sulphate tablets themselves. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010028-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010028-sec-0037"></div> <p>To assess the effects and adverse effects of ephedrine in people with autoimmune MG, transient neonatal MG, and the congenital myasthenic syndromes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010028-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010028-sec-0038"></div> <section id="CD010028-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010028-sec-0040"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) and quasi‐RCTs. Where no evidence from RCTs or quasi‐RCTs was available, we summarised the results of non‐randomised studies in the 'Discussion' section of this review. </p> </section> <section id="CD010028-sec-0041"> <h4 class="title">Types of participants</h4> <p>We considered studies of adults and children with a diagnosis of myasthenia gravis (MG), neonatal myasthenia gravis (NMG) or congenital myasthenic syndromes (CMSs), based on clinical presentation, and electromyographic, immunological or genetic tests. Where no data on electromyographic, immunological or genetic tests were available, participants were included under the heading 'not genetically characterised CMS' (in the case of CMS) or 'unknown form of myasthenia' (all other cases). </p> </section> <section id="CD010028-sec-0042"> <h4 class="title">Types of interventions</h4> <p>We considered any RCT or quasi‐RCT that compared the effects of ephedrine as single treatment or as add‐on treatment with any other active treatment, placebo, or no treatment. For the non‐randomised studies, we included all studies that described the effect of ephedrine as single or add‐on treatment. </p> </section> <section id="CD010028-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD010028-sec-0044"> <h5 class="title">Primary outcomes</h5> <p>Change in a score measuring endurance within one to 14 days of the start of treatment, preferably measured by a recognised and validated instrument, such as the Quantitative Myasthenia Gravis Scale (QMG). </p> </section> <section id="CD010028-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010028-list-0001"> <li> <p>Change in a score measuring endurance more than 14 days after the start of treatment, preferably measured by a recognised and validated instrument, such as the QMG. </p> </li> <li> <p>Change in a score measuring muscle strength, preferably measured by a recognised and validated instrument, such as the Manual Muscle Test (MMT), within one to 14 days and more than 14 days after the start of treatment. </p> </li> <li> <p>Change in a score measuring quality of life, preferably measured by a validated instrument (e.g. MG‐QOL15) within one to 14 days and more than 14 days after the start of treatment. </p> </li> <li> <p>Post‐intervention Myasthenia Gravis Foundation of America (MGFA) status more than 14 days after the start of treatment. </p> </li> <li> <p>Adverse events.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010028-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010028-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Neuromuscular Disease Group Specialised Register (17 November 2014), Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 10 in <i>The Cochrane Library</i>), MEDLINE (January 1966 to March 2013) and EMBASE (January 1980 to March 2013). We did not use a filter to identify RCTs and quasi‐RCTs. The detailed search strategies are listed in the appendices: <a href="./appendices#CD010028-sec-0092">Appendix 1</a> (MEDLINE), <a href="./appendices#CD010028-sec-0093">Appendix 2</a> (EMBASE), <a href="./appendices#CD010028-sec-0094">Appendix 3</a> (CENTRAL) and <a href="./appendices#CD010028-sec-0095">Appendix 4</a> (Cochrane Neuromuscular Disease Group Specialized Register). </p> <p>We scanned conference abstracts of the following conferences of the last 10 years for relevant studies, insofar as they were digitally available: International Congress on Neuromuscular Diseases (ICNMD), Peripheral Nerve Society, European Neurological Society, American Society of Human Genetics, European Society of Human Genetics, European Federation of Neurological Societies, European Congress of Immunology, International Congress of Neuroimmunology, World Muscle Society, American Academy of Neurology, Dutch Society for Immunology, International Congress of Myology, International Conference on Myasthenia Gravis and Related Disorders, World Congress of Neurology, Federation of European Neuroscience Societies, TREAT‐NMD international conference, Dutch Endo‐Neuro‐Psycho meeting, New Directions in Biology and Disease of Skeletal Muscle Conference. We searched prospective trial registers using the online International Clinical Trials Registry Platform (ICTRP). </p> </section> <section id="CD010028-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We checked all references in the publications thus identified and contacted authors to identify any additional published or unpublished data. We aimed to contact any commercial manufacturers of ephedrine sulphate to ask about any study results on the efficacy of ephedrine for MG, NMG and CMS, but we did not identify any commercial manufacturers. </p> </section> </section> <section id="CD010028-sec-0049"> <h3 class="title" id="CD010028-sec-0049">Data collection and analysis</h3> <section id="CD010028-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CV and AZ) independently screened titles and abstracts of the publications identified through the searches in an unblinded manner to assess eligibility for inclusion in this review. Where necessary, we examined the full‐text publication. We excluded studies that did not meet the inclusion criteria described above. We resolved disagreements between review authors by discussion, by referral to a third review author (JV), or both. In the case of publications of studies in languages other than English, Dutch, German, French, Spanish or Italian, a native speaker assessed eligibility and performed the data extraction. </p> </section> <section id="CD010028-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AZ and SW) independently extracted characteristics of each study using a standardised data extraction form. A third author (CV) then checked the results. Extracted data included: </p> <p> <ul id="CD010028-list-0002"> <li> <p>study characteristics, including study design features, setting and funding source;</p> </li> <li> <p>characteristics of trial participants: inclusion and exclusion criteria, number of participants, gender and age distribution, how the diagnosis was established, severity and duration of disease; </p> </li> <li> <p>characteristics of the intervention: sample size, type, dose, frequency, route of administration and duration of treatment; </p> </li> <li> <p>characteristics of the outcome measures: measurement instruments used, features of these instruments (for example, the range of a scale and whether a high or a low score indicates a favourable outcome) and definitions of cut‐off points (where appropriate); </p> </li> <li> <p>risk of bias (see below).</p> </li> </ul> </p> <p>To determine the design of each study, we used the checklist developed by the 'Non‐Randomised Studies Methods Group', which is described in Chapter 13 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010028-bbs2-0103" title="ReevesBC , DeeksJJ , HigginsJPT , WellsGA . Chapter 13: Including non‐randomized studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Reeves 2011</a>). For adverse events, we would have extracted the methods which were used for monitoring these events (for example, spontaneous reporting, participant checklist or diary), how these were reported (for example, whether any participants were excluded from the adverse events analysis), and the duration of follow‐up (<a href="./references#CD010028-bbs2-0074" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Loke 2011</a>), but these characteristics were seldom reported. Where necessary, we contacted study authors to obtain further information. </p> </section> <section id="CD010028-sec-0052"> <h4 class="title">Data synthesis</h4> <p>Because there was no evidence available from RCTs or quasi‐RCTs, we described results from non‐randomised studies narratively. The analysis methods we would have used for RCTs or quasi‐RCTs are described in <a href="./appendices#CD010028-sec-0096">Appendix 5</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010028-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010028-sec-0053"></div> <section id="CD010028-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD010028-sec-0055"> <h4 class="title">Results of the search</h4> <p>Our search resulted in 140 potentially eligible articles. After removal of duplicates, 113 articles remained. We identified a further 17 conference abstracts. Going through the reference lists of retrieved papers resulted in another 25 possibly relevant publications. We found nine references by a serendipitous search of ScienceDirect. Contacting authors of relevant papers resulted in one more reference being identified. We found one reference for an ongoing cross‐over RCT for ephedrine in CMS due to mutations in the COLQ gene (<a href="./references#CD010028-bbs2-0001" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">NCT00541216</a>). </p> <p>We excluded 12 publications based on the title or abstract alone. We retrieved 154 references in full text to determine eligibility, which resulted in a further 81 references being excluded. We further processed the remaining 73 references. A flow diagram of the inclusion process is presented in <a href="#CD010028-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010028-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (a supplementary search shortly before publication resulted in 16 references, no RCTs or quasi‐RCTs and seven additional studies to be assessed for inclusion in the Discussion at the next update)." data-id="CD010028-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010028.pub2/media/CDSR/CD010028/image_n/nCD010028-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (a supplementary search shortly before publication resulted in 16 references, no RCTs or quasi‐RCTs and seven additional studies to be assessed for inclusion in the Discussion at the next update). </p> </div> </div> </div> <p>We updated the search shortly before publication and identified no RCTs or quasi‐RCTs. We identified seven additional studies to assess for inclusion in the Discussion at the next update (<a href="./references#CD010028-bbs2-0030" title="DuranGS , UzunhanTA , EkiciB , CitakA , AydinliN , CaliskanM . Severe scoliosis in a patient with COLQ mutation and congenital myasthenic syndrome: a clue for diagnosis. Acta Neurologica Belgica2013;113(4):531‐2. [PUBMED: 23371844 ] ">Duran 2013</a>; <a href="./references#CD010028-bbs2-0045" title="EymardB , StojkovicT , SternbergD , RichardP , NicoleS , FournierE , et al. Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy. The French National Congenital Myasthenic Syndrome Network experience. [Syndromes myasthéniques congénitaux: difficultés diagnostiques, évolution et pronostic, thérapeutique. L'expérience du réseau national &quot;Syndromes Myasthéniques Congénitaux&quot;]. Revue Neurologique2013;169(Suppl 1):S45‐55. [PUBMED: 23452772 ] ">Eymard 2013</a>; <a href="./references#CD010028-bbs2-0052" title="HantaiD , NicoleS , EymardB . Congenital myasthenic syndromes: an update. Current Opinion in Neurology2013;26(5):561‐8. [PUBMED: 23995276] ">Hantai 2013</a>; <a href="./references#CD010028-bbs2-0068" title="KleinA , PittMC , McHughJC , NiksEH , SewryCA , PhadkeR , et al. DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children. Neuromuscular Disorders2013;23(11):883‐91. [PUBMED: 23831158] ">Klein 2013</a>; <a href="./references#CD010028-bbs2-0076" title="LorenzoniPJ , ScolaRH , KayCSK , LochmüllerH , WerneckLC . Congenital myasthenic syndrome and minicore‐like myopathy with DOK7 mutation. Muscle &amp; Nerve2013;48(1):151‐2. [PUBMED: 23657916] ">Lorenzoni 2013</a>; <a href="./references#CD010028-bbs2-0093" title="NicoleS , ChaouchA , TorbergsenT , BaucheS , DeBruyckereE , FontenilleM‐J , et al. Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain2014;137(9):2429‐43. [PUBMED: 24951643 ] ">Nicole 2014</a>; <a href="./references#CD010028-bbs2-0130" title="WittingN , VissingJ . Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome. JAMA Neurology2014;71(3):350‐4. [PUBMED: 24425145] ">Witting 2014</a>). </p> </section> <section id="CD010028-sec-0056"> <h4 class="title">Included studies</h4> <p>We did not identify any publications of RCTs or quasi‐RCTs which investigated the effect of ephedrine on MG, NMG, or any of the CMSs. However, we identified 73 references of non‐randomised studies and describe them in the <a href="#CD010028-sec-0059">Discussion</a> section. Five of these are on myasthenia gravis (2 MuSK MG, 3 AChR MG) and 52 on CMS. The exact type of myasthenia could not be determined in a further 16 publications, mainly because these were older papers from before current diagnostic methods became available. These papers are therefore discussed separately (see 'Unknown form of myasthenia' below). We identified no papers on the effects of ephedrine in NMG. </p> <p>In total, the 73 publications describe 53 different non‐randomised studies: six before‐and‐after studies (five CMS, one 'unknown form'), 29 case series (22 CMS, seven 'unknown form') and 18 case reports (five MG, 10 CMS, three 'unknown form'). The ongoing clinical trial that was identified was described as a cross‐over RCT, but thus far results have only partially been published in the form of a case report, which we cover in this review. Some case series included people with different types of CMS. In these cases, the results for each type of CMS are discussed separately under the appropriate headings in the <a href="#CD010028-sec-0059">Discussion</a>. Only those people in each case series who were treated with ephedrine are included in the descriptions of the publications below. A summary of the findings is presented in <a href="#CD010028-tbl-0001">Table 1</a>. </p> <div class="table" id="CD010028-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summaries of findings of non‐randomised studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of myasthenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Before‐after studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Case series</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Case reports</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of people in review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ephedrine dose (orally, unless stated otherwise)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Autoimmune</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AChR MG</p> <p>(<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>; <a href="./references#CD010028-bbs2-0077" title="MacdonaldAM , KeenRI , PughND . Myasthenia gravis and atracurium: a case report. British Journal of Anaesthesia1984;56(6):651‐4. ">Macdonald 1984</a>; <a href="./references#CD010028-bbs2-0082" title="McAlpineJK , ThomsonJE . Myasthenia gravis and Schmidt syndrome. Postgraduate Medical Journal1988;64(756):787‐8. ">McAlpine 1988</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 to 40 mg 4 times daily</p> <p>or 4 mg I.V. Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in muscle strength in 3 people. Adverse effects reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MuSK MG</p> <p>(<a href="./references#CD010028-bbs2-0034" title="EhlerE , LattaJ . Myasthenia with positive anti‐MuSK‐positive antibodies in a young man: a case report [Myastenie s pozitivními anti‐MuSK protilátkami u mladého muže: kazuistika]. Ceska a Slovenska Neurologie a Neurochirurgie2008;71(1):101‐4. ">Ehler 2008</a>; <a href="./references#CD010028-bbs2-0053" title="HaranM , SchattnerA , MateA , StarobinD , HaranG , ShtalridM . Can a rare form of myasthenia gravis shed additional light on disease mechanisms?. Clinical Neurology and Neurosurgery2013;115(5):562‐6. ">Haran 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to 50 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in symptoms in 2 people. Adverse effects reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neonatal myasthenia gravis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Congenital myasthenic syndromes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Presynaptic</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHAT</p> <p>(<a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a> and <a href="./references#CD010028-bbs2-0105" title="RobbSA , MuntoniF , SimondsAK . Respiratory management of congenital myasthenic syndromes in childhood: Workshop 8th December 2009, UCL Institute of Neurology, London, UK. Neuromuscular Disorders2010;20(12):833‐8. ">Robb 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in symptoms in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presynaptic other</p> <p>(<a href="./references#CD010028-bbs2-0036" title="EngelAG , OhnoK , SineSM . Congenital myasthenic syndromes: progress over the past decade. Muscle &amp; Nerve2003;27(1):4‐25. ">Engel 2003</a> and <a href="./references#CD010028-bbs2-0078" title="MaselliRA , KongDZ , BoweCM , McDonaldCM , EllisWG , AgiusMA , et al. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology2001;57(2):279‐89. ">Maselli 2001</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in muscle strength and fatigue in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Synaptic</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AGRN</p> <p>(<a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0060" title="HuzéC , BauchéS , RichardP , ChevessierF , GoillotE , GaudonK , et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. American Journal of Human Genetics2009;85(2):155‐67. ">Huzé 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg/day</p> <p>or 2 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in muscle strength, endurance and well‐being in 2 people. No change in 1 person. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COLQ</p> <p>(<a href="./references#CD010028-bbs2-0003" title="AdamovičováM , FabriciováK , JakubíkováM , PříhodováI , KlementP , SýkoraP , et al. Congenital myasthenia as a cause of respiratory failure in two infants and a toddler: case reports [Kongenitální myastenie jako příčina respiračního selhání u dvou kojenců a batolete: kazuistiky]. Ceska a Slovenska Neurologie a Neurochirurgie2012;75(6):757‐62. ">Adamovičová 2012</a>; <a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>, <a href="./references#CD010028-bbs2-0011" title="BestuéM , CapabloJL , Sáenz de CabezónA , López‐PisónJ , BenaventeI , LarrodéP , et al. [Mutación Y430S en un grupo de cinco pacientes con miastenia congénita por déficit de acetilcolinesterasa (AChE). Es una mutación fundacional hispánica?]. Comunicacones Orales de la Sociedad Española de Neurología2006;21(9):455‐550. ">Bestué 2006</a>, <a href="./references#CD010028-bbs2-0013" title="BrengmanJ , Capablo‐LiesaJL , Bestue‐CardielM , López‐PisónJ , Peña‐SeguraJL , Benavente‐AguilarI , et al. Ephedrine treatment of seven patients with congenital endplate (EP) acetylcholinesterase (AChE) deficiency. Neuromuscular Disorders2006;16(Suppl 1):S129. ">Brengman 2006</a> and <a href="./references#CD010028-bbs2-0038" title="EngelAG , ShenXM , SelcenD , SineSM . Further observations in congenital myasthenic syndromes. Annals of the New York Academy of Sciences2008;1132:104‐13. ">Engel 2008</a>; </p> <p><a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a>; <a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a> and <a href="./references#CD010028-bbs2-0001" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">NCT00541216</a>; <a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0086" title="MihaylovaV , MüllerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Phenotypical spectrum of congenital myasthenic syndrome caused by mutations in COLQ gene. Journal of Neurology2008;255(Suppl 2):185. ">Mihaylova 2008a</a>, <a href="./references#CD010028-bbs2-0087" title="MihaylovaV , MullerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Clinical and molecular genetic findings in 22 COLQ‐mutant CMS patients. Neurology2008;70(11):A426. ">Mihaylova 2008b</a>, <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a> and <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>, <a href="./references#CD010028-bbs2-0126" title="WargonI , RichardP , KuntzerT , NafissiS , GaudonK , SternbergD , et al. P5.17 Congenital Myasthenic Syndromes with COLQ mutations: long term follow‐up. Neuromuscular Disorders2011;21(9):728‐9. ">Wargon 2011</a> and <a href="./references#CD010028-bbs2-0007" title="BauduinH , ServaisL , RichardP , SternbergD , FournierE , LaforetP , et al. Pregnancy outcome in congenital myasthenic syndromes. Neuromuscular Disorders2011;21(9‐10):728. ">Bauduin 2011</a>; <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to 200 mg/day (adults)</p> <p>or 0.5 to 5 mg/kg/day (children). Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in endurance, muscle strength or both in about half of 29 people. Possible improvements in quality of life and respiration. </p> <p>No change reported in 3 people. Adverse effects reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMB2</p> <p>(<a href="./references#CD010028-bbs2-0079" title="MaselliRA , NgJJ , AndersonJA , CagneyO , ArredondoJ , WilliamsC , et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. Journal of Medical Genetics2009;46(3):203‐8. ">Maselli 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Postsynaptic</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHRNE</p> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; <a href="./references#CD010028-bbs2-0065" title="KhanA , HussainN , GosalakkalJA . Bulbar dysfunction: An early presentation of congenital myasthenic syndrome in three infants. Journal of Pediatric Neurosciences2011;6(2):124‐6. ">Khan 2011</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>; <a href="./references#CD010028-bbs2-0081" title="MaselliRA , ArredondoJ , CagneyO , MozaffarT , SkinnerS , YousifS , et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. Clinical Genetics2011;80(5):444‐51. ">Maselli 2011</a>; <a href="./references#CD010028-bbs2-0094" title="NogajskiJH , KiernanMC , OuvrierRA , AndrewsPI . Congenital myasthenic syndromes. Journal of Clinical Neuroscience2009;16(1):1‐11. ">Nogajski 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 mg twice daily. Not reported in most.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in 9/14 people. No change in 4 people. Adverse effects suspected.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DOK7</p> <p>(<a href="./references#CD010028-bbs2-0004" title="AndersonJA , NgJJ , BoweC , McDonaldC , RichmanDP , WollmannRL , et al. Variable phenotypes associated with mutations in DOK7. Muscle &amp; Nerve2008;37(4):448‐56. ">Anderson 2008</a>; <a href="./references#CD010028-bbs2-0009" title="Ben AmmarA , PetitF , AlexandriN , GaudonK , BauchéS , RoucheA , et al. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. Journal of Neurology2010;257(5):754‐66. ">Ben Ammar 2010</a> and <a href="./references#CD010028-bbs2-0107" title="SarkozyA , LochmüllerH . Neuromuscular disorders and 2010: recent advances. Journal of Neurology2010;257(12):2117‐21. ">Sarkozy 2010</a>; <a href="./references#CD010028-bbs2-0015" title="BurkeG , AllenD , ArunachalamR , BeesonD , HammansS . A treatable muscle disease. Practical Neurology2009;9(4):233‐6. ">Burke 2009</a>; <a href="./references#CD010028-bbs2-0017" title="BurkeG , HiscockA , KleinA , NiksEH , MainM , ManzurAY , et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular disorders2013;23(2):170‐5. ">Burke 2013</a> and <a href="./references#CD010028-bbs2-0016" title="BurkeG , HiscockA , KleinA , NgJ , ManzurAY , DeVileC , et al. Salbutamol treatment in children with DOK7 congenital myasthenic syndrome. European Journal of Paediatric Neurology2011;15(Suppl 1):S20. ">Burke 2011</a>; <a href="./references#CD010028-bbs2-0027" title="Della MarinaA , AbichtA , ScharaU . Congenital myasthenic syndromes [Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie]. Nervenheilkunde2011;30(10):797‐804. ">Della Marina 2011</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a> and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>; <a href="./references#CD010028-bbs2-0095" title="PalaceJ , LashleyD , Newsom‐DavisJ , CossinsJ , MaxwellS , KennettR , et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain2007;130(Pt 6):1507‐15. ">Palace 2007</a> and <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>; <a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>; <a href="./references#CD010028-bbs2-0111" title="ScharaU , Della MarinaA , AbichtA . Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics2012;43(4):184‐93. ">Schara 2012</a>; <a href="./references#CD010028-bbs2-0114" title="SelcenD , MiloneM , ShenX‐M , HarperCM , StansAA , WiebenED , et al. Dok‐7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Annals of Neurology2008;64(1):71‐87. ">Selcen 2008</a>; <a href="./references#CD010028-bbs2-0119" title="SrourM , BolducV , GuergueltchevaV , LochmüllerH , GendronD , ShevellMI , et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscular Disorders2010;20(7):453‐7. ">Srour 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 to 100 mg/day</p> <p>or 0.5 to 1.0 mg/kg/day (children). Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in endurance, muscle strength, quality of life, or unspecified improvements in majority of 40 people. No response in 4 people. Adverse effects reported in 10 people. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fast channel</p> <p>(<a href="./references#CD010028-bbs2-0097" title="PalaceJ , LashleyD , BaileyS , JayawantS , CarrA , McConvilleJ , et al. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscular Disorders2012;22(2):112‐7. ">Palace 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possibly no effect in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limb‐girdle</p> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in all 5 people.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MuSK</p> <p>(<a href="./references#CD010028-bbs2-0080" title="MaselliRA , ArredondoJ , CagneyÓ , NgJJ , AndersonJA , WilliamsC , et al. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK‐Dok‐7 interaction. Human Molecular Genetics2010;19(12):2370‐9. ">Maselli 2010</a>; <a href="./references#CD010028-bbs2-0089" title="MihaylovaV , SalihMAM , MukhtarMM , AbuzeidHA , El‐SadigSM , von derHagenM , et al. Refinement of the clinical phenotype in MUSK‐related congenital myasthenic syndromes. Neurology2009;73(22):1926‐28. ">Mihaylova 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response in 1 person. Not tolerated in the other person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RAPSN</p> <p>(<a href="./references#CD010028-bbs2-0005" title="BanwellBL , OhnoK , SiebJP , EngelAG . Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4‐diaminopyridine. Neuromuscular Disorders2004;14(3):202‐7. ">Banwell 2004</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in all 4 people.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow channel</p> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible slight improvement in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Not genetically characterised CMS</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0046" title="FeliceK , RelvaG . Ephedrine in the treatment of congenital myasthenic syndrome. Muscle &amp; Nerve1996; Vol. 19, issue 6:799‐800. ">Felice 1996</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0120" title="TerblancheN , MaxwellC , KeunenJ , CarvalhoJC . Obstetric and anesthetic management of severe congenital myasthenia syndrome. Anesthesia and Analgesia2008;107(4):1313‐5. ">Terblanche 2008</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 ‐ 50 mg oral,</p> <p>or 25 mg twice daily oral,</p> <p>or 25 mg I.M. Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No objective improvements in</p> <p>forced vital capacity, muscle strength, or RNS/CMAP decrement. Possible subjective improvements in strength. Adverse effects reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Unknown form of myasthenia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010028-bbs2-0019" title="Chan‐LuiWY , LeungNK , LauTTY . Myasthenia gravis in Chinese children. Developmental Medicine &amp; Child Neurology1984;26(6):717‐24. ">Chan‐Lui 1984</a>; <a href="./references#CD010028-bbs2-0025" title="DalkaraT , KansuT , KayaalpO , ZileliT . Pupillary dysfunction in myasthenia gravis: possible involvement of ciliary ganglion. Hacettepe Medical Journal1988;21(4):269‐74. ">Dalkara 1988</a>; <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a>, <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a> and <a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>; <a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>; <a href="./references#CD010028-bbs2-0099" title="PattenBM , HartA , LovelaceR . Multiple sclerosis associated with defects in neuromuscular transmission. Journal of Neurology, Neurosurgery, &amp; Psychiatry1972;35(3):385‐94. ">Patten 1972</a>; <a href="./references#CD010028-bbs2-0100" title="PearceJMS . Mary Broadfoot Walker (1888‐1974): a historic discovery in myasthenia gravis. European Neurology2005;53(1):51‐3. ">Pearce 2005</a>, <a href="./references#CD010028-bbs2-0061" title="JohnstonJD . Special section on myasthenia: the contributions of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. Journal of the History of the Neurosciences: Basic and Clinical Perspectives2005;14(2):121‐37. ">Johnston 2005</a>, <a href="./references#CD010028-bbs2-0124" title="WalkerMB . Treatment of myasthenia gravis with physostigmine. Lancet1934;223(5779):1200‐1. ">Walker 1934</a> and <a href="./references#CD010028-bbs2-0125" title="WalkerMB . A contribution to the study of myasthenia gravis [MD thesis]. Edinburgh, UK: University of Edinburgh, 1935. ">Walker 1935</a>; <a href="./references#CD010028-bbs2-0113" title="SchwarzH . Urecholine in myasthenia gravis. Canadian Medical Association Journal1955;72(5):346‐51. ">Schwarz 1955</a>; <a href="./references#CD010028-bbs2-0117" title="SimpsonJF , WesterbergMR , MageeKR . Myasthenia gravis: an analysis of 295 cases. Acta Neurologica Scandinavica1966;42 Suppl 23:1‐27. ">Simpson 1966</a>; <a href="./references#CD010028-bbs2-0122" title="VietsH , SchwabR . The diagnosis and treatment of myasthenia gravis: with special reference to the use of prostigmine. Journal of the American Medical Association1939;113(7):559‐63. ">Viets 1939</a>; <a href="./references#CD010028-bbs2-0128" title="WilsonA , StonerHB . Prostigmin and ephedrine in myasthenia gravis. Lancet1944;243(6292):429‐31. ">Wilson 1944</a>; <a href="./references#CD010028-bbs2-0132" title="YahrMD , DavisTK . Myasthenia gravis ‐ its occurrence in a seven‐year‐old female child. Journal of Pediatrics1944;25(3):218‐25. ">Yahr 1944</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 ‐ 96 mg oral,</p> <p>or &lt; 64 mg S.C.,</p> <p>or 3% eye drop</p> <p>solution. Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in a majority of people. No response in a minority. Adverse effects reported. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AChR: acetylcholine receptor; CMAP: compound muscle action potential; CMS: congenital myasthenic syndrome; I.M.: intramuscular; I.V.: intravenous; MG: myasthenia gravis; MuSK: muscle specific tyrosine kinase; n/a: not applicable; RNS: repetitive nerve stimulation; S.C.: subcutaneous </p> </div> </div> </section> </section> <section id="CD010028-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>Because we include no RCTs or quasi‐RCTs, we have not carried out a formal assessment of risk of bias. We assume a high risk of bias (according to the Cochrane 'Risk of bias' tool) for all non‐randomised studies. </p> </section> <section id="CD010028-sec-0058"> <h3 class="title" id="CD010028-sec-0058">Effects of interventions</h3> <p>Due to a lack of RCTs or quasi‐RCTs, we could not establish the effect of ephedrine on MG, NMG and CMSs. </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010028-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010028-sec-0059"></div> <p>Our search did not identify any randomised controlled trials (RCTs) or quasi‐RCTs, and therefore the results of non‐randomised studies are described here, as per protocol (<a href="./references#CD010028-bbs2-0135" title="VrintenC , WeinreichSS , ScholtenRJPM , VerschuurenJJGM . Ephedrine for myasthenia gravis. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD010028] ">Vrinten 2012</a>). The update of our search shortly before publication resulted in seven additional studies that are awaiting assessment for inclusion in the Discussion at the next update (<a href="./references#CD010028-bbs2-0030" title="DuranGS , UzunhanTA , EkiciB , CitakA , AydinliN , CaliskanM . Severe scoliosis in a patient with COLQ mutation and congenital myasthenic syndrome: a clue for diagnosis. Acta Neurologica Belgica2013;113(4):531‐2. [PUBMED: 23371844 ] ">Duran 2013</a>; <a href="./references#CD010028-bbs2-0045" title="EymardB , StojkovicT , SternbergD , RichardP , NicoleS , FournierE , et al. Congenital myasthenic syndromes: difficulties in the diagnosis, course and prognosis, and therapy. The French National Congenital Myasthenic Syndrome Network experience. [Syndromes myasthéniques congénitaux: difficultés diagnostiques, évolution et pronostic, thérapeutique. L'expérience du réseau national &quot;Syndromes Myasthéniques Congénitaux&quot;]. Revue Neurologique2013;169(Suppl 1):S45‐55. [PUBMED: 23452772 ] ">Eymard 2013</a>; <a href="./references#CD010028-bbs2-0052" title="HantaiD , NicoleS , EymardB . Congenital myasthenic syndromes: an update. Current Opinion in Neurology2013;26(5):561‐8. [PUBMED: 23995276] ">Hantai 2013</a>; <a href="./references#CD010028-bbs2-0068" title="KleinA , PittMC , McHughJC , NiksEH , SewryCA , PhadkeR , et al. DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children. Neuromuscular Disorders2013;23(11):883‐91. [PUBMED: 23831158] ">Klein 2013</a>; <a href="./references#CD010028-bbs2-0076" title="LorenzoniPJ , ScolaRH , KayCSK , LochmüllerH , WerneckLC . Congenital myasthenic syndrome and minicore‐like myopathy with DOK7 mutation. Muscle &amp; Nerve2013;48(1):151‐2. [PUBMED: 23657916] ">Lorenzoni 2013</a>; <a href="./references#CD010028-bbs2-0093" title="NicoleS , ChaouchA , TorbergsenT , BaucheS , DeBruyckereE , FontenilleM‐J , et al. Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain2014;137(9):2429‐43. [PUBMED: 24951643 ] ">Nicole 2014</a>; <a href="./references#CD010028-bbs2-0130" title="WittingN , VissingJ . Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome. JAMA Neurology2014;71(3):350‐4. [PUBMED: 24425145] ">Witting 2014</a>). </p> <section id="CD010028-sec-0060"> <h3 class="title" id="CD010028-sec-0060">Autoimmune myasthenia gravis</h3> <section id="CD010028-sec-0061"> <h4 class="title">AChR MG</h4> <p>Three case reports described the effects of ephedrine in people with AChR myasthenia gravis (MG) (<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>; <a href="./references#CD010028-bbs2-0077" title="MacdonaldAM , KeenRI , PughND . Myasthenia gravis and atracurium: a case report. British Journal of Anaesthesia1984;56(6):651‐4. ">Macdonald 1984</a>; <a href="./references#CD010028-bbs2-0082" title="McAlpineJK , ThomsonJE . Myasthenia gravis and Schmidt syndrome. Postgraduate Medical Journal1988;64(756):787‐8. ">McAlpine 1988</a>). All received ephedrine 15 to 40 mg four times daily orally in combination with pyridostigmine or with pyridostigmine and neostigmine. Muscle strength improved in two individuals (<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>; <a href="./references#CD010028-bbs2-0077" title="MacdonaldAM , KeenRI , PughND . Myasthenia gravis and atracurium: a case report. British Journal of Anaesthesia1984;56(6):651‐4. ">Macdonald 1984</a>) and in one person symptoms were “well controlled” (<a href="./references#CD010028-bbs2-0082" title="McAlpineJK , ThomsonJE . Myasthenia gravis and Schmidt syndrome. Postgraduate Medical Journal1988;64(756):787‐8. ">McAlpine 1988</a>). In one person, ephedrine was withdrawn preoperatively and started again postoperatively without any signs of increased muscle fatigue (<a href="./references#CD010028-bbs2-0077" title="MacdonaldAM , KeenRI , PughND . Myasthenia gravis and atracurium: a case report. British Journal of Anaesthesia1984;56(6):651‐4. ">Macdonald 1984</a>). An intravenous injection of 4 mg ephedrine reversed ptosis "immediately" in one person before she was put on oral medication (<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>). </p> <p>One person, who had experienced an unexplained psychotic episode several years earlier, developed psychotic symptoms (delusion of persecution) several weeks after ephedrine was started (<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>). This latest psychotic episode was attributed to treatment with ephedrine, which has a stimulatory effect on the central nervous system. The psychotic symptoms almost completely resolved after withdrawal of ephedrine. </p> </section> <section id="CD010028-sec-0062"> <h4 class="title">MuSK MG</h4> <p>Two case reports described the effects of ephedrine in MuSK MG (<a href="./references#CD010028-bbs2-0034" title="EhlerE , LattaJ . Myasthenia with positive anti‐MuSK‐positive antibodies in a young man: a case report [Myastenie s pozitivními anti‐MuSK protilátkami u mladého muže: kazuistika]. Ceska a Slovenska Neurologie a Neurochirurgie2008;71(1):101‐4. ">Ehler 2008</a>; <a href="./references#CD010028-bbs2-0053" title="HaranM , SchattnerA , MateA , StarobinD , HaranG , ShtalridM . Can a rare form of myasthenia gravis shed additional light on disease mechanisms?. Clinical Neurology and Neurosurgery2013;115(5):562‐6. ">Haran 2013</a>). One person was treated with ephedrine, prednisone and azathioprine. This person had “slight vegetative complaints” after the first two days of ephedrine, but the dose could gradually be increased to 50 mg three times daily, which was well‐tolerated and caused myasthenic symptoms to stabilise (<a href="./references#CD010028-bbs2-0034" title="EhlerE , LattaJ . Myasthenia with positive anti‐MuSK‐positive antibodies in a young man: a case report [Myastenie s pozitivními anti‐MuSK protilátkami u mladého muže: kazuistika]. Ceska a Slovenska Neurologie a Neurochirurgie2008;71(1):101‐4. ">Ehler 2008</a>). The other person worsened on standard treatment, but her endurance level improved and her need for respiratory support decreased when salbutamol was given. She improved even further after substitution of salbutamol with a “longer acting beta‐agonist” and 12 mg ephedrine three times daily (<a href="./references#CD010028-bbs2-0053" title="HaranM , SchattnerA , MateA , StarobinD , HaranG , ShtalridM . Can a rare form of myasthenia gravis shed additional light on disease mechanisms?. Clinical Neurology and Neurosurgery2013;115(5):562‐6. ">Haran 2013</a>). </p> </section> </section> <section id="CD010028-sec-0063"> <h3 class="title" id="CD010028-sec-0063">Neonatal myasthenia gravis</h3> <p>We did not identify any publications on the effects of ephedrine in neonatal myasthenia gravis. </p> </section> <section id="CD010028-sec-0064"> <h3 class="title" id="CD010028-sec-0064">Congenital myasthenic syndromes (CMSs)</h3> <section id="CD010028-sec-0065"> <h4 class="title">Presynaptic CMS</h4> <section id="CD010028-sec-0066"> <h5 class="title">CHAT</h5> <p>We identified a case series of 46 people, 10 of whom had been treated with ephedrine (<a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>). One of these 10 had a CMS based on a mutation in CHAT (MIM ID: <b>*</b>118490; this person was also reported by <a href="./references#CD010028-bbs2-0105" title="RobbSA , MuntoniF , SimondsAK . Respiratory management of congenital myasthenic syndromes in childhood: Workshop 8th December 2009, UCL Institute of Neurology, London, UK. Neuromuscular Disorders2010;20(12):833‐8. ">Robb 2010</a> in a workshop report). Ephedrine in combination with pyridostigmine led to symptom improvement in this person. No adverse effects were reported. </p> </section> <section id="CD010028-sec-0067"> <h5 class="title">Genetically uncharacterised presynaptic CMS</h5> <p><a href="./references#CD010028-bbs2-0078" title="MaselliRA , KongDZ , BoweCM , McDonaldCM , EllisWG , AgiusMA , et al. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology2001;57(2):279‐89. ">Maselli 2001</a> (also in <a href="./references#CD010028-bbs2-0036" title="EngelAG , OhnoK , SineSM . Congenital myasthenic syndromes: progress over the past decade. Muscle &amp; Nerve2003;27(1):4‐25. ">Engel 2003</a>) described a case series of three people with genetically uncharacterised presynaptic CMS. One of them was treated with ephedrine and pyridostigmine, which resulted in slight improvements in muscle strength and fatigability. </p> </section> </section> <section id="CD010028-sec-0068"> <h4 class="title">Synaptic CMS</h4> <section id="CD010028-sec-0069"> <h5 class="title">AGRN</h5> <p>We identified two case series describing a total of three people with CMS due to mutations in AGRN who received ephedrine (MIM ID: <b>*</b>103320; one case was presented by B Eymard in <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0060" title="HuzéC , BauchéS , RichardP , ChevessierF , GoillotE , GaudonK , et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. American Journal of Human Genetics2009;85(2):155‐67. ">Huzé 2009</a>). Two adult siblings received ephedrine 50 mg/day for three days and then 2 mg/kg each morning, which led to improvements in muscle strength, endurance, and general well‐being (<a href="./references#CD010028-bbs2-0060" title="HuzéC , BauchéS , RichardP , ChevessierF , GoillotE , GaudonK , et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. American Journal of Human Genetics2009;85(2):155‐67. ">Huzé 2009</a>). In contrast, ephedrine had resulted in “little change to her neuromuscular weakness” in a third person in whom it had recently been started (<a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>). </p> </section> <section id="CD010028-sec-0070"> <h5 class="title">COLQ</h5> <p>Results of an ongoing trial and treatment results of 29 people with CMS due to mutations in COLQ (MIM ID* 603033) who were treated with ephedrine were described in one case report (<a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a>; <a href="./references#CD010028-bbs2-0001" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">NCT00541216</a>) and nine case series (<a href="./references#CD010028-bbs2-0003" title="AdamovičováM , FabriciováK , JakubíkováM , PříhodováI , KlementP , SýkoraP , et al. Congenital myasthenia as a cause of respiratory failure in two infants and a toddler: case reports [Kongenitální myastenie jako příčina respiračního selhání u dvou kojenců a batolete: kazuistiky]. Ceska a Slovenska Neurologie a Neurochirurgie2012;75(6):757‐62. ">Adamovičová 2012</a>; <a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>, also described in <a href="./references#CD010028-bbs2-0011" title="BestuéM , CapabloJL , Sáenz de CabezónA , López‐PisónJ , BenaventeI , LarrodéP , et al. [Mutación Y430S en un grupo de cinco pacientes con miastenia congénita por déficit de acetilcolinesterasa (AChE). Es una mutación fundacional hispánica?]. Comunicacones Orales de la Sociedad Española de Neurología2006;21(9):455‐550. ">Bestué 2006</a>, <a href="./references#CD010028-bbs2-0013" title="BrengmanJ , Capablo‐LiesaJL , Bestue‐CardielM , López‐PisónJ , Peña‐SeguraJL , Benavente‐AguilarI , et al. Ephedrine treatment of seven patients with congenital endplate (EP) acetylcholinesterase (AChE) deficiency. Neuromuscular Disorders2006;16(Suppl 1):S129. ">Brengman 2006</a>, and <a href="./references#CD010028-bbs2-0038" title="EngelAG , ShenXM , SelcenD , SineSM . Further observations in congenital myasthenic syndromes. Annals of the New York Academy of Sciences2008;1132:104‐13. ">Engel 2008</a>; <a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a>; one case series presented by S Robb in <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>, also described in <a href="./references#CD010028-bbs2-0126" title="WargonI , RichardP , KuntzerT , NafissiS , GaudonK , SternbergD , et al. P5.17 Congenital Myasthenic Syndromes with COLQ mutations: long term follow‐up. Neuromuscular Disorders2011;21(9):728‐9. ">Wargon 2011</a> and <a href="./references#CD010028-bbs2-0007" title="BauduinH , ServaisL , RichardP , SternbergD , FournierE , LaforetP , et al. Pregnancy outcome in congenital myasthenic syndromes. Neuromuscular Disorders2011;21(9‐10):728. ">Bauduin 2011</a>; <a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0086" title="MihaylovaV , MüllerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Phenotypical spectrum of congenital myasthenic syndrome caused by mutations in COLQ gene. Journal of Neurology2008;255(Suppl 2):185. ">Mihaylova 2008a</a>, also described in <a href="./references#CD010028-bbs2-0087" title="MihaylovaV , MullerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Clinical and molecular genetic findings in 22 COLQ‐mutant CMS patients. Neurology2008;70(11):A426. ">Mihaylova 2008b</a>, <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a> and <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; and <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>). Reported dosages of ephedrine ranged from 50 to 200 mg/day divided over several doses for adults (<a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>; <a href="./references#CD010028-bbs2-0011" title="BestuéM , CapabloJL , Sáenz de CabezónA , López‐PisónJ , BenaventeI , LarrodéP , et al. [Mutación Y430S en un grupo de cinco pacientes con miastenia congénita por déficit de acetilcolinesterasa (AChE). Es una mutación fundacional hispánica?]. Comunicacones Orales de la Sociedad Española de Neurología2006;21(9):455‐550. ">Bestué 2006</a>; <a href="./references#CD010028-bbs2-0013" title="BrengmanJ , Capablo‐LiesaJL , Bestue‐CardielM , López‐PisónJ , Peña‐SeguraJL , Benavente‐AguilarI , et al. Ephedrine treatment of seven patients with congenital endplate (EP) acetylcholinesterase (AChE) deficiency. Neuromuscular Disorders2006;16(Suppl 1):S129. ">Brengman 2006</a>; <a href="./references#CD010028-bbs2-0038" title="EngelAG , ShenXM , SelcenD , SineSM . Further observations in congenital myasthenic syndromes. Annals of the New York Academy of Sciences2008;1132:104‐13. ">Engel 2008</a>; <a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a>; <a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>; <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a>; <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>) and 0.5 to 1 mg/kg/day in combination with pyridostigmine (<a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>) or 2 to 5 mg/kg/day without pyridostigmine in children (<a href="./references#CD010028-bbs2-0003" title="AdamovičováM , FabriciováK , JakubíkováM , PříhodováI , KlementP , SýkoraP , et al. Congenital myasthenia as a cause of respiratory failure in two infants and a toddler: case reports [Kongenitální myastenie jako příčina respiračního selhání u dvou kojenců a batolete: kazuistiky]. Ceska a Slovenska Neurologie a Neurochirurgie2012;75(6):757‐62. ">Adamovičová 2012</a>; <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a>). </p> <p>Seventeen people experienced improvements in endurance or muscle strength or both, such as walking distance and timed arm raise (<a href="./references#CD010028-bbs2-0007" title="BauduinH , ServaisL , RichardP , SternbergD , FournierE , LaforetP , et al. Pregnancy outcome in congenital myasthenic syndromes. Neuromuscular Disorders2011;21(9‐10):728. ">Bauduin 2011</a>; <a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>; <a href="./references#CD010028-bbs2-0011" title="BestuéM , CapabloJL , Sáenz de CabezónA , López‐PisónJ , BenaventeI , LarrodéP , et al. [Mutación Y430S en un grupo de cinco pacientes con miastenia congénita por déficit de acetilcolinesterasa (AChE). Es una mutación fundacional hispánica?]. Comunicacones Orales de la Sociedad Española de Neurología2006;21(9):455‐550. ">Bestué 2006</a>; <a href="./references#CD010028-bbs2-0013" title="BrengmanJ , Capablo‐LiesaJL , Bestue‐CardielM , López‐PisónJ , Peña‐SeguraJL , Benavente‐AguilarI , et al. Ephedrine treatment of seven patients with congenital endplate (EP) acetylcholinesterase (AChE) deficiency. Neuromuscular Disorders2006;16(Suppl 1):S129. ">Brengman 2006</a>; <a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a> ; <a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a>; <a href="./references#CD010028-bbs2-0038" title="EngelAG , ShenXM , SelcenD , SineSM . Further observations in congenital myasthenic syndromes. Annals of the New York Academy of Sciences2008;1132:104‐13. ">Engel 2008</a>; <a href="./references#CD010028-bbs2-0086" title="MihaylovaV , MüllerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Phenotypical spectrum of congenital myasthenic syndrome caused by mutations in COLQ gene. Journal of Neurology2008;255(Suppl 2):185. ">Mihaylova 2008a</a>, <a href="./references#CD010028-bbs2-0087" title="MihaylovaV , MullerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Clinical and molecular genetic findings in 22 COLQ‐mutant CMS patients. Neurology2008;70(11):A426. ">Mihaylova 2008b</a>, <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0126" title="WargonI , RichardP , KuntzerT , NafissiS , GaudonK , SternbergD , et al. P5.17 Congenital Myasthenic Syndromes with COLQ mutations: long term follow‐up. Neuromuscular Disorders2011;21(9):728‐9. ">Wargon 2011</a>; <a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>; <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>). </p> <p>Quality of life also seemed to improve in a number of people, although this was not assessed by validated instruments. Some striking anecdotes were reported, however. For example, one person who was previously unable to walk 200 metres without resting became able to play soccer and became a "normally active teenager" after ephedrine treatment was started (<a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>). Another became "independent in activities of daily living" (<a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>). A third experienced a "resolution of dysphonia and dysphagia" and went from being wheelchair‐dependent to needing only a crutch for mobility indoors (<a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>). </p> <p>In addition, several people experienced improvements in respiration, with reports of reduced needs for assisted ventilation (<a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>), allowing weaning off ventilation altogether (<a href="./references#CD010028-bbs2-0007" title="BauduinH , ServaisL , RichardP , SternbergD , FournierE , LaforetP , et al. Pregnancy outcome in congenital myasthenic syndromes. Neuromuscular Disorders2011;21(9‐10):728. ">Bauduin 2011</a>), or improvements in spirometry measures (<a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a>; <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a>; <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>). </p> <p>Treatment with ephedrine was described as being "beneficial" in published results of a further five people (<a href="./references#CD010028-bbs2-0003" title="AdamovičováM , FabriciováK , JakubíkováM , PříhodováI , KlementP , SýkoraP , et al. Congenital myasthenia as a cause of respiratory failure in two infants and a toddler: case reports [Kongenitální myastenie jako příčina respiračního selhání u dvou kojenců a batolete: kazuistiky]. Ceska a Slovenska Neurologie a Neurochirurgie2012;75(6):757‐62. ">Adamovičová 2012</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>) and in seven people who started ephedrine treatment as part of an ongoing trial (<a href="./references#CD010028-bbs2-0001" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">NCT00541216</a>, personal communication), but details of treatment effects were not provided. Three people did not benefit from ephedrine (<a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a>; <a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>) and the results of treatment were not described in two people (<a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>). </p> <p>Of note, <a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a> described two siblings with the same genetic mutation and a similar phenotype, but different responses to ephedrine. One responded well, while the other's response was "disappointing". In contrast, <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a> reported two siblings with the same genetic mutation, but different phenotypes, who both seemed to benefit from ephedrine, although not to the same extent. </p> <p>Not all studies reported whether there were adverse effects of treatment. However, no major adverse effects were seen in three people (<a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>, personal communication; <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>). One person experienced "transient side effects" on higher doses of ephedrine (<a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a>) and two people experienced tachycardia, which led to the decision to discontinue ephedrine after one week in one person (<a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a>; <a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>). One person had used ephedrine for 20 years before it was discontinued at age 37. She showed no response to ephedrine when it was started again at age 60 (<a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>). </p> </section> <section id="CD010028-sec-0071"> <h5 class="title">LAMB2</h5> <p>One case report (<a href="./references#CD010028-bbs2-0079" title="MaselliRA , NgJJ , AndersonJA , CagneyO , ArredondoJ , WilliamsC , et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. Journal of Medical Genetics2009;46(3):203‐8. ">Maselli 2009</a>) described the effect of ephedrine in a person with a CMS based on mutations in LAMB2 (MIM ID: <b>*</b>150325). The person went into respiratory crisis following a trial of anticholinesterases but "responded well" to ephedrine. </p> </section> </section> <section id="CD010028-sec-0072"> <h4 class="title">Postsynaptic CMS</h4> <section id="CD010028-sec-0073"> <h5 class="title">CHRNE</h5> <p>A total of 14 people with CMS caused by mutations in CHRNE (MIM ID: <b>*</b>100725) were described in three case series (<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>) and four case reports (<a href="./references#CD010028-bbs2-0065" title="KhanA , HussainN , GosalakkalJA . Bulbar dysfunction: An early presentation of congenital myasthenic syndrome in three infants. Journal of Pediatric Neurosciences2011;6(2):124‐6. ">Khan 2011</a>; <a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>; <a href="./references#CD010028-bbs2-0081" title="MaselliRA , ArredondoJ , CagneyO , MozaffarT , SkinnerS , YousifS , et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. Clinical Genetics2011;80(5):444‐51. ">Maselli 2011</a>; <a href="./references#CD010028-bbs2-0094" title="NogajskiJH , KiernanMC , OuvrierRA , AndrewsPI . Congenital myasthenic syndromes. Journal of Clinical Neuroscience2009;16(1):1‐11. ">Nogajski 2009</a>). Most people received a combination of ephedrine and AChEIs (pyridostigmine) (<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0081" title="MaselliRA , ArredondoJ , CagneyO , MozaffarT , SkinnerS , YousifS , et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. Clinical Genetics2011;80(5):444‐51. ">Maselli 2011</a>; <a href="./references#CD010028-bbs2-0094" title="NogajskiJH , KiernanMC , OuvrierRA , AndrewsPI . Congenital myasthenic syndromes. Journal of Clinical Neuroscience2009;16(1):1‐11. ">Nogajski 2009</a>). Two people received ephedrine (7.5 mg twice daily in one person) together with pyridostigmine and 3,4‐DAP (<a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; <a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>), and in one person together with neostigmine (<a href="./references#CD010028-bbs2-0065" title="KhanA , HussainN , GosalakkalJA . Bulbar dysfunction: An early presentation of congenital myasthenic syndrome in three infants. Journal of Pediatric Neurosciences2011;6(2):124‐6. ">Khan 2011</a>). </p> <p>Nine of 14 people showed a favourable response to ephedrine (<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0065" title="KhanA , HussainN , GosalakkalJA . Bulbar dysfunction: An early presentation of congenital myasthenic syndrome in three infants. Journal of Pediatric Neurosciences2011;6(2):124‐6. ">Khan 2011</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>; <a href="./references#CD010028-bbs2-0081" title="MaselliRA , ArredondoJ , CagneyO , MozaffarT , SkinnerS , YousifS , et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. Clinical Genetics2011;80(5):444‐51. ">Maselli 2011</a>; <a href="./references#CD010028-bbs2-0094" title="NogajskiJH , KiernanMC , OuvrierRA , AndrewsPI . Congenital myasthenic syndromes. Journal of Clinical Neuroscience2009;16(1):1‐11. ">Nogajski 2009</a>). Swallowing time improved in three people (<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>). One person initially experienced improvements in fatigue, muscle strength, respiration, and chewing and swallowing (<a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>). However, this person's response to ephedrine stabilised and then decreased again, leading to worsening of muscle strength and fatigue (<a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>; personal communication). Dose changes did not improve her condition at this point and it was discontinued. In contrast, other authors reported sustained responses over 1.5 and 10 years of follow‐up in two people (<a href="./references#CD010028-bbs2-0065" title="KhanA , HussainN , GosalakkalJA . Bulbar dysfunction: An early presentation of congenital myasthenic syndrome in three infants. Journal of Pediatric Neurosciences2011;6(2):124‐6. ">Khan 2011</a>; <a href="./references#CD010028-bbs2-0094" title="NogajskiJH , KiernanMC , OuvrierRA , AndrewsPI . Congenital myasthenic syndromes. Journal of Clinical Neuroscience2009;16(1):1‐11. ">Nogajski 2009</a>). Four people did not respond to treatment with ephedrine (<a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>). Treatment results were not reported for one person (<a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>). Adverse effects were not reported, but it was noted that one person was always very anxious after taking ephedrine, and a habituation or addiction syndrome was observed when ephedrine was discontinued in this person (<a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>; personal communication). </p> </section> <section id="CD010028-sec-0074"> <h5 class="title">DOK7</h5> <p>Forty people with a CMS based on mutations in DOK7 (MIM ID: *610285) who received ephedrine were described in 19 publications of 12 studies, which included four before‐and‐after studies (<a href="./references#CD010028-bbs2-0015" title="BurkeG , AllenD , ArunachalamR , BeesonD , HammansS . A treatable muscle disease. Practical Neurology2009;9(4):233‐6. ">Burke 2009</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, also described by J Palace in <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, and in <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a> and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>; <a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>; <a href="./references#CD010028-bbs2-0119" title="SrourM , BolducV , GuergueltchevaV , LochmüllerH , GendronD , ShevellMI , et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscular Disorders2010;20(7):453‐7. ">Srour 2010</a>), one case study (<a href="./references#CD010028-bbs2-0111" title="ScharaU , Della MarinaA , AbichtA . Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics2012;43(4):184‐93. ">Schara 2012</a>), and seven case series (<a href="./references#CD010028-bbs2-0004" title="AndersonJA , NgJJ , BoweC , McDonaldC , RichmanDP , WollmannRL , et al. Variable phenotypes associated with mutations in DOK7. Muscle &amp; Nerve2008;37(4):448‐56. ">Anderson 2008</a>; <a href="./references#CD010028-bbs2-0009" title="Ben AmmarA , PetitF , AlexandriN , GaudonK , BauchéS , RoucheA , et al. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. Journal of Neurology2010;257(5):754‐66. ">Ben Ammar 2010</a> and <a href="./references#CD010028-bbs2-0107" title="SarkozyA , LochmüllerH . Neuromuscular disorders and 2010: recent advances. Journal of Neurology2010;257(12):2117‐21. ">Sarkozy 2010</a>; <a href="./references#CD010028-bbs2-0017" title="BurkeG , HiscockA , KleinA , NiksEH , MainM , ManzurAY , et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular disorders2013;23(2):170‐5. ">Burke 2013</a> and <a href="./references#CD010028-bbs2-0016" title="BurkeG , HiscockA , KleinA , NgJ , ManzurAY , DeVileC , et al. Salbutamol treatment in children with DOK7 congenital myasthenic syndrome. European Journal of Paediatric Neurology2011;15(Suppl 1):S20. ">Burke 2011</a>; <a href="./references#CD010028-bbs2-0027" title="Della MarinaA , AbichtA , ScharaU . Congenital myasthenic syndromes [Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie]. Nervenheilkunde2011;30(10):797‐804. ">Della Marina 2011</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0095" title="PalaceJ , LashleyD , Newsom‐DavisJ , CossinsJ , MaxwellS , KennettR , et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain2007;130(Pt 6):1507‐15. ">Palace 2007</a>; <a href="./references#CD010028-bbs2-0114" title="SelcenD , MiloneM , ShenX‐M , HarperCM , StansAA , WiebenED , et al. Dok‐7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Annals of Neurology2008;64(1):71‐87. ">Selcen 2008</a>; <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>). Dosages varied between 7.5 and 100 mg/day (paediatric doses: 0.5 to 1.0 mg/kg/day), sometimes in combination with 3,4‐DAP or pyridostigmine. </p> <p>Endurance or muscle strength or both improved in 15 people, as measured by various tests, such as the two‐minute walk test, QMG test, and timed arm and leg raise (<a href="./references#CD010028-bbs2-0015" title="BurkeG , AllenD , ArunachalamR , BeesonD , HammansS . A treatable muscle disease. Practical Neurology2009;9(4):233‐6. ">Burke 2009</a> ; <a href="./references#CD010028-bbs2-0017" title="BurkeG , HiscockA , KleinA , NiksEH , MainM , ManzurAY , et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular disorders2013;23(2):170‐5. ">Burke 2013</a> and <a href="./references#CD010028-bbs2-0016" title="BurkeG , HiscockA , KleinA , NgJ , ManzurAY , DeVileC , et al. Salbutamol treatment in children with DOK7 congenital myasthenic syndrome. European Journal of Paediatric Neurology2011;15(Suppl 1):S20. ">Burke 2011</a>; <a href="./references#CD010028-bbs2-0027" title="Della MarinaA , AbichtA , ScharaU . Congenital myasthenic syndromes [Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie]. Nervenheilkunde2011;30(10):797‐804. ">Della Marina 2011</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a>, and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>; <a href="./references#CD010028-bbs2-0111" title="ScharaU , Della MarinaA , AbichtA . Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics2012;43(4):184‐93. ">Schara 2012</a>; <a href="./references#CD010028-bbs2-0119" title="SrourM , BolducV , GuergueltchevaV , LochmüllerH , GendronD , ShevellMI , et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscular Disorders2010;20(7):453‐7. ">Srour 2010</a>). Quality of life (QOL) seemed to have improved in a similar number of people, although this was not assessed with validated outcome measures (<a href="./references#CD010028-bbs2-0015" title="BurkeG , AllenD , ArunachalamR , BeesonD , HammansS . A treatable muscle disease. Practical Neurology2009;9(4):233‐6. ">Burke 2009</a>; <a href="./references#CD010028-bbs2-0027" title="Della MarinaA , AbichtA , ScharaU . Congenital myasthenic syndromes [Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie]. Nervenheilkunde2011;30(10):797‐804. ">Della Marina 2011</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a>, and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>; <a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>). Some striking improvements in QOL were reported: many people became more independent and able to participate in school, work and social life (<a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>). One person had been unable to climb stairs in the evenings, but was unrestricted in activities of daily living after two years of treatment with ephedrine (<a href="./references#CD010028-bbs2-0027" title="Della MarinaA , AbichtA , ScharaU . Congenital myasthenic syndromes [Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie]. Nervenheilkunde2011;30(10):797‐804. ">Della Marina 2011</a>). Another could do five squats before ephedrine was started, but was able to do 50 afterwards. A third person used to walk with crutches but was able to walk unassisted, go for jogs and do sit‐ups after ephedrine was started, and a fourth had been using a wheelchair for longer distances but was now able to go on prolonged shopping trips and wear high heels (<a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>). Treatment effects were described as "beneficial" in another 13 people, but no further details were given (<a href="./references#CD010028-bbs2-0004" title="AndersonJA , NgJJ , BoweC , McDonaldC , RichmanDP , WollmannRL , et al. Variable phenotypes associated with mutations in DOK7. Muscle &amp; Nerve2008;37(4):448‐56. ">Anderson 2008</a>; <a href="./references#CD010028-bbs2-0009" title="Ben AmmarA , PetitF , AlexandriN , GaudonK , BauchéS , RoucheA , et al. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. Journal of Neurology2010;257(5):754‐66. ">Ben Ammar 2010</a> and <a href="./references#CD010028-bbs2-0107" title="SarkozyA , LochmüllerH . Neuromuscular disorders and 2010: recent advances. Journal of Neurology2010;257(12):2117‐21. ">Sarkozy 2010</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0095" title="PalaceJ , LashleyD , Newsom‐DavisJ , CossinsJ , MaxwellS , KennettR , et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain2007;130(Pt 6):1507‐15. ">Palace 2007</a> and <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>; <a href="./references#CD010028-bbs2-0114" title="SelcenD , MiloneM , ShenX‐M , HarperCM , StansAA , WiebenED , et al. Dok‐7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Annals of Neurology2008;64(1):71‐87. ">Selcen 2008</a>). Four people did not benefit from ephedrine (<a href="./references#CD010028-bbs2-0004" title="AndersonJA , NgJJ , BoweC , McDonaldC , RichmanDP , WollmannRL , et al. Variable phenotypes associated with mutations in DOK7. Muscle &amp; Nerve2008;37(4):448‐56. ">Anderson 2008</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a>, and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>). </p> <p>Adverse effects were reported in a quarter of people (10 of 40), including tachycardia (two people), epistaxis (two people), sleep disturbances (two people), muscle cramps, sweating, nervous feeling, cold extremities, dry mouth and hypertension (<a href="./references#CD010028-bbs2-0015" title="BurkeG , AllenD , ArunachalamR , BeesonD , HammansS . A treatable muscle disease. Practical Neurology2009;9(4):233‐6. ">Burke 2009</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a>, and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>; <a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>; and <a href="./references#CD010028-bbs2-0119" title="SrourM , BolducV , GuergueltchevaV , LochmüllerH , GendronD , ShevellMI , et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscular Disorders2010;20(7):453‐7. ">Srour 2010</a>, personal communication). One person experienced a habituation of beneficial effects after 22 months and a dose increase led to unacceptable adverse effects. For three people, adverse effects were the reason to discontinue ephedrine. The others rated their adverse effects as minimal compared to the beneficial effects of ephedrine. Ephedrine was replaced by salbutamol in two people because of adverse effects in one person (<a href="./references#CD010028-bbs2-0119" title="SrourM , BolducV , GuergueltchevaV , LochmüllerH , GendronD , ShevellMI , et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscular Disorders2010;20(7):453‐7. ">Srour 2010</a>) and for "parental convenience" in the other (<a href="./references#CD010028-bbs2-0017" title="BurkeG , HiscockA , KleinA , NiksEH , MainM , ManzurAY , et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular disorders2013;23(2):170‐5. ">Burke 2013</a> and <a href="./references#CD010028-bbs2-0016" title="BurkeG , HiscockA , KleinA , NgJ , ManzurAY , DeVileC , et al. Salbutamol treatment in children with DOK7 congenital myasthenic syndrome. European Journal of Paediatric Neurology2011;15(Suppl 1):S20. ">Burke 2011</a>). Finally, it is noteworthy that one before‐and‐after study used vital capacity and repetitive nerve stimulation (RNS) studies to evaluate the effects of ephedrine treatment, but the authors commented that these measures were inadequate to monitor the effects of treatment (<a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>). </p> </section> <section id="CD010028-sec-0075"> <h5 class="title">Fast‐channel syndromes</h5> <p>We identified one case series that described a single person with a fast channel CMS who received ephedrine, possibly together with pyridostigmine and 3,4‐DAP (<a href="./references#CD010028-bbs2-0097" title="PalaceJ , LashleyD , BaileyS , JayawantS , CarrA , McConvilleJ , et al. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscular Disorders2012;22(2):112‐7. ">Palace 2012</a>). Ephedrine did not seem to have an effect. However, the authors state it may not have been tried for long enough for any benefit to become apparent before it was stopped again for reasons that were not reported. </p> </section> <section id="CD010028-sec-0076"> <h5 class="title">Limb‐girdle CMS</h5> <p>We identified three case series which described a total of five people with limb‐girdle CMS who received ephedrine (presented by J Palace in <a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>). The last paper described the effects of ephedrine in four people, but one person was later found to have DOK7 CMS and was also described by <a href="./references#CD010028-bbs2-0095" title="PalaceJ , LashleyD , Newsom‐DavisJ , CossinsJ , MaxwellS , KennettR , et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain2007;130(Pt 6):1507‐15. ">Palace 2007</a>. This individual was therefore not included here, but in the DOK7 section. All of the remaining five people responded favourably to ephedrine, including some who had failed to respond, or had deteriorated, on pyridostigmine. </p> </section> <section id="CD010028-sec-0077"> <h5 class="title">MUSK</h5> <p>We found one case series (<a href="./references#CD010028-bbs2-0089" title="MihaylovaV , SalihMAM , MukhtarMM , AbuzeidHA , El‐SadigSM , von derHagenM , et al. Refinement of the clinical phenotype in MUSK‐related congenital myasthenic syndromes. Neurology2009;73(22):1926‐28. ">Mihaylova 2009</a>) and one case report (<a href="./references#CD010028-bbs2-0080" title="MaselliRA , ArredondoJ , CagneyÓ , NgJJ , AndersonJA , WilliamsC , et al. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK‐Dok‐7 interaction. Human Molecular Genetics2010;19(12):2370‐9. ">Maselli 2010</a>), which together described two people with CMS based on mutations in the MUSK gene (MIM ID: <b>*</b>601296) who received ephedrine. One person did not tolerate it and the other showed no response to ephedrine. </p> </section> <section id="CD010028-sec-0078"> <h5 class="title">RAPSN</h5> <p>Three case series reported on four people with CMS based on mutations in RAPSN (MIM ID: <b>*</b>601592) who received ephedrine (<a href="./references#CD010028-bbs2-0005" title="BanwellBL , OhnoK , SiebJP , EngelAG . Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4‐diaminopyridine. Neuromuscular Disorders2004;14(3):202‐7. ">Banwell 2004</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; J Colomer in <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>). Ephedrine doses were not reported, but all four people responded favourably. Two of the four were siblings, with compound heterozygous mutations in RAPSN and a heterozygous mutation in DOK7 (<a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>). They received ephedrine in combination with AChEIs and 3,4‐DAP. Symptoms improved in both, but one sibling remained dependent on nocturnal ventilation. A third person’s strength improved such that he was able to walk unassisted for the first time (<a href="./references#CD010028-bbs2-0005" title="BanwellBL , OhnoK , SiebJP , EngelAG . Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4‐diaminopyridine. Neuromuscular Disorders2004;14(3):202‐7. ">Banwell 2004</a>). Two people later switched to 3,4‐DAP, which was better tolerated (<a href="./references#CD010028-bbs2-0005" title="BanwellBL , OhnoK , SiebJP , EngelAG . Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4‐diaminopyridine. Neuromuscular Disorders2004;14(3):202‐7. ">Banwell 2004</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>). </p> </section> <section id="CD010028-sec-0079"> <h5 class="title">Slow‐channel syndromes</h5> <p>A single person with a slow‐channel syndrome who received ephedrine was described in a case series of people with various types of CMS. This person showed a slight improvement (J Palace in <a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>). </p> </section> </section> <section id="CD010028-sec-0080"> <h4 class="title">Not genetically characterised CMS</h4> <p>We identified two case series that partly described the same people (J Palace in <a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>), one before‐and‐after study (<a href="./references#CD010028-bbs2-0046" title="FeliceK , RelvaG . Ephedrine in the treatment of congenital myasthenic syndrome. Muscle &amp; Nerve1996; Vol. 19, issue 6:799‐800. ">Felice 1996</a>), and one case report (<a href="./references#CD010028-bbs2-0120" title="TerblancheN , MaxwellC , KeunenJ , CarvalhoJC . Obstetric and anesthetic management of severe congenital myasthenia syndrome. Anesthesia and Analgesia2008;107(4):1313‐5. ">Terblanche 2008</a>) on the effects of ephedrine in genetically uncharacterised CMS. Altogether, they described the results of ephedrine in five people. The before‐and‐after study failed to find significant changes in forced vital capacity (FVC) and muscle strength (Medical Research Council (MRC) Scale) scores two hours after a single dose (25 to 50 mg, orally) or one week after treatment with ephedrine (25 mg twice daily, orally) in three people (<a href="./references#CD010028-bbs2-0046" title="FeliceK , RelvaG . Ephedrine in the treatment of congenital myasthenic syndrome. Muscle &amp; Nerve1996; Vol. 19, issue 6:799‐800. ">Felice 1996</a>). The per cent decrement during RNS studies remained unchanged two hours after 25 to 50 mg ephedrine orally or one week after 25 mg ephedrine twice daily orally. Similarly, the per cent decrement of the compound muscle action potential (CMAP) following 3‐Hz RNS failed to change significantly 20, 40, or 60 minutes after 25 mg intramuscular (i.m.) ephedrine. However, all recipients described moderate subjective improvements in strength and stamina. Adverse effects included "mild" tachycardia after 50 mg oral and 25 mg i.m. ephedrine (<a href="./references#CD010028-bbs2-0046" title="FeliceK , RelvaG . Ephedrine in the treatment of congenital myasthenic syndrome. Muscle &amp; Nerve1996; Vol. 19, issue 6:799‐800. ">Felice 1996</a>). The effect of ephedrine was not described in detail in the other reports, but both people in these reports improved (<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0120" title="TerblancheN , MaxwellC , KeunenJ , CarvalhoJC . Obstetric and anesthetic management of severe congenital myasthenia syndrome. Anesthesia and Analgesia2008;107(4):1313‐5. ">Terblanche 2008</a>). </p> </section> </section> <section id="CD010028-sec-0081"> <h3 class="title" id="CD010028-sec-0081">Unknown form of myasthenia</h3> <p>Three case reports (<a href="./references#CD010028-bbs2-0025" title="DalkaraT , KansuT , KayaalpO , ZileliT . Pupillary dysfunction in myasthenia gravis: possible involvement of ciliary ganglion. Hacettepe Medical Journal1988;21(4):269‐74. ">Dalkara 1988</a>; <a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>; <a href="./references#CD010028-bbs2-0132" title="YahrMD , DavisTK . Myasthenia gravis ‐ its occurrence in a seven‐year‐old female child. Journal of Pediatrics1944;25(3):218‐25. ">Yahr 1944</a>), seven case series (<a href="./references#CD010028-bbs2-0019" title="Chan‐LuiWY , LeungNK , LauTTY . Myasthenia gravis in Chinese children. Developmental Medicine &amp; Child Neurology1984;26(6):717‐24. ">Chan‐Lui 1984</a>; <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a>, also described in <a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a> and <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a>; <a href="./references#CD010028-bbs2-0099" title="PattenBM , HartA , LovelaceR . Multiple sclerosis associated with defects in neuromuscular transmission. Journal of Neurology, Neurosurgery, &amp; Psychiatry1972;35(3):385‐94. ">Patten 1972</a>; <a href="./references#CD010028-bbs2-0100" title="PearceJMS . Mary Broadfoot Walker (1888‐1974): a historic discovery in myasthenia gravis. European Neurology2005;53(1):51‐3. ">Pearce 2005</a>, also described in <a href="./references#CD010028-bbs2-0061" title="JohnstonJD . Special section on myasthenia: the contributions of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. Journal of the History of the Neurosciences: Basic and Clinical Perspectives2005;14(2):121‐37. ">Johnston 2005</a>, <a href="./references#CD010028-bbs2-0124" title="WalkerMB . Treatment of myasthenia gravis with physostigmine. Lancet1934;223(5779):1200‐1. ">Walker 1934</a> and <a href="./references#CD010028-bbs2-0125" title="WalkerMB . A contribution to the study of myasthenia gravis [MD thesis]. Edinburgh, UK: University of Edinburgh, 1935. ">Walker 1935</a>; <a href="./references#CD010028-bbs2-0113" title="SchwarzH . Urecholine in myasthenia gravis. Canadian Medical Association Journal1955;72(5):346‐51. ">Schwarz 1955</a>; <a href="./references#CD010028-bbs2-0117" title="SimpsonJF , WesterbergMR , MageeKR . Myasthenia gravis: an analysis of 295 cases. Acta Neurologica Scandinavica1966;42 Suppl 23:1‐27. ">Simpson 1966</a>; <a href="./references#CD010028-bbs2-0122" title="VietsH , SchwabR . The diagnosis and treatment of myasthenia gravis: with special reference to the use of prostigmine. Journal of the American Medical Association1939;113(7):559‐63. ">Viets 1939</a>) and one before‐and‐after study (<a href="./references#CD010028-bbs2-0128" title="WilsonA , StonerHB . Prostigmin and ephedrine in myasthenia gravis. Lancet1944;243(6292):429‐31. ">Wilson 1944</a>) described a total of 196 people who were treated with ephedrine. Daily oral dosages of ephedrine ranged from 15 to 96 mg, usually divided over several doses, and given either alone or in combination with various other drugs, such as glycine, pyridostigmine, prednisolone, potassium salts, neostigmine, and ambenonium. Subcutaneous doses of up to 64 mg were reported, either alone or in combination with neostigmine (<a href="./references#CD010028-bbs2-0128" title="WilsonA , StonerHB . Prostigmin and ephedrine in myasthenia gravis. Lancet1944;243(6292):429‐31. ">Wilson 1944</a>). In one report, ephedrine was given as an eye drop solution of 3% (<a href="./references#CD010028-bbs2-0025" title="DalkaraT , KansuT , KayaalpO , ZileliT . Pupillary dysfunction in myasthenia gravis: possible involvement of ciliary ganglion. Hacettepe Medical Journal1988;21(4):269‐74. ">Dalkara 1988</a>). </p> <p>152 people improved when ephedrine was given, but no further details were reported (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>; <a href="./references#CD010028-bbs2-0099" title="PattenBM , HartA , LovelaceR . Multiple sclerosis associated with defects in neuromuscular transmission. Journal of Neurology, Neurosurgery, &amp; Psychiatry1972;35(3):385‐94. ">Patten 1972</a>; <a href="./references#CD010028-bbs2-0100" title="PearceJMS . Mary Broadfoot Walker (1888‐1974): a historic discovery in myasthenia gravis. European Neurology2005;53(1):51‐3. ">Pearce 2005</a>, <a href="./references#CD010028-bbs2-0061" title="JohnstonJD . Special section on myasthenia: the contributions of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. Journal of the History of the Neurosciences: Basic and Clinical Perspectives2005;14(2):121‐37. ">Johnston 2005</a>, <a href="./references#CD010028-bbs2-0124" title="WalkerMB . Treatment of myasthenia gravis with physostigmine. Lancet1934;223(5779):1200‐1. ">Walker 1934</a> and <a href="./references#CD010028-bbs2-0125" title="WalkerMB . A contribution to the study of myasthenia gravis [MD thesis]. Edinburgh, UK: University of Edinburgh, 1935. ">Walker 1935</a>; <a href="./references#CD010028-bbs2-0113" title="SchwarzH . Urecholine in myasthenia gravis. Canadian Medical Association Journal1955;72(5):346‐51. ">Schwarz 1955</a>; <a href="./references#CD010028-bbs2-0117" title="SimpsonJF , WesterbergMR , MageeKR . Myasthenia gravis: an analysis of 295 cases. Acta Neurologica Scandinavica1966;42 Suppl 23:1‐27. ">Simpson 1966</a>; <a href="./references#CD010028-bbs2-0122" title="VietsH , SchwabR . The diagnosis and treatment of myasthenia gravis: with special reference to the use of prostigmine. Journal of the American Medical Association1939;113(7):559‐63. ">Viets 1939</a>). Twenty‐eight people did not show a response (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>; <a href="./references#CD010028-bbs2-0100" title="PearceJMS . Mary Broadfoot Walker (1888‐1974): a historic discovery in myasthenia gravis. European Neurology2005;53(1):51‐3. ">Pearce 2005</a>, <a href="./references#CD010028-bbs2-0061" title="JohnstonJD . Special section on myasthenia: the contributions of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. Journal of the History of the Neurosciences: Basic and Clinical Perspectives2005;14(2):121‐37. ">Johnston 2005</a>, <a href="./references#CD010028-bbs2-0124" title="WalkerMB . Treatment of myasthenia gravis with physostigmine. Lancet1934;223(5779):1200‐1. ">Walker 1934</a> and <a href="./references#CD010028-bbs2-0125" title="WalkerMB . A contribution to the study of myasthenia gravis [MD thesis]. Edinburgh, UK: University of Edinburgh, 1935. ">Walker 1935</a>; <a href="./references#CD010028-bbs2-0117" title="SimpsonJF , WesterbergMR , MageeKR . Myasthenia gravis: an analysis of 295 cases. Acta Neurologica Scandinavica1966;42 Suppl 23:1‐27. ">Simpson 1966</a>; <a href="./references#CD010028-bbs2-0122" title="VietsH , SchwabR . The diagnosis and treatment of myasthenia gravis: with special reference to the use of prostigmine. Journal of the American Medical Association1939;113(7):559‐63. ">Viets 1939</a>; <a href="./references#CD010028-bbs2-0132" title="YahrMD , DavisTK . Myasthenia gravis ‐ its occurrence in a seven‐year‐old female child. Journal of Pediatrics1944;25(3):218‐25. ">Yahr 1944</a>), and one person worsened (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>). Improvements in muscle strength were reported for two people by <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a> (also described in <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a> and <a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>) and <a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>. Furthermore, in the series of before‐and‐after trials in ten people conducted by <a href="./references#CD010028-bbs2-0128" title="WilsonA , StonerHB . Prostigmin and ephedrine in myasthenia gravis. Lancet1944;243(6292):429‐31. ">Wilson 1944</a>, a greater increase in muscle strength and longer duration of effect were observed when a subcutaneous injection of ephedrine was added to neostigmine, compared to neostigmine alone. However, in the majority of people muscle strength did not increase when an oral dose of ephedrine was added to oral neostigmine, although the effects of neostigmine did last longer (<a href="./references#CD010028-bbs2-0128" title="WilsonA , StonerHB . Prostigmin and ephedrine in myasthenia gravis. Lancet1944;243(6292):429‐31. ">Wilson 1944</a>). We identified two studies that solely investigated the effect of ephedrine on ocular symptoms (<a href="./references#CD010028-bbs2-0019" title="Chan‐LuiWY , LeungNK , LauTTY . Myasthenia gravis in Chinese children. Developmental Medicine &amp; Child Neurology1984;26(6):717‐24. ">Chan‐Lui 1984</a>; <a href="./references#CD010028-bbs2-0025" title="DalkaraT , KansuT , KayaalpO , ZileliT . Pupillary dysfunction in myasthenia gravis: possible involvement of ciliary ganglion. Hacettepe Medical Journal1988;21(4):269‐74. ">Dalkara 1988</a>). Ptosis and ophthalmoplegia responded poorly to ephedrine in two people (<a href="./references#CD010028-bbs2-0019" title="Chan‐LuiWY , LeungNK , LauTTY . Myasthenia gravis in Chinese children. Developmental Medicine &amp; Child Neurology1984;26(6):717‐24. ">Chan‐Lui 1984</a>). Eye drops of 3% ephedrine solution resulted in an increased pupillary diameter in one person (<a href="./references#CD010028-bbs2-0025" title="DalkaraT , KansuT , KayaalpO , ZileliT . Pupillary dysfunction in myasthenia gravis: possible involvement of ciliary ganglion. Hacettepe Medical Journal1988;21(4):269‐74. ">Dalkara 1988</a>). </p> <p>In addition, several authors described attempts to decrease the dose of ephedrine, or to withdraw ephedrine altogether, to ascertain whether an observed effect was really due to ephedrine (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>; <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a> and <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a>; <a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>; <a href="./references#CD010028-bbs2-0099" title="PattenBM , HartA , LovelaceR . Multiple sclerosis associated with defects in neuromuscular transmission. Journal of Neurology, Neurosurgery, &amp; Psychiatry1972;35(3):385‐94. ">Patten 1972</a>). Five people were able to decrease the dose of ephedrine without an increase in symptoms (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>). Temporary withdrawal of ephedrine in three people resulted in an increase in muscle weakness, disability or both in all three (<a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a> and <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a>; <a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>; <a href="./references#CD010028-bbs2-0099" title="PattenBM , HartA , LovelaceR . Multiple sclerosis associated with defects in neuromuscular transmission. Journal of Neurology, Neurosurgery, &amp; Psychiatry1972;35(3):385‐94. ">Patten 1972</a>). </p> <p>Most studies did not describe adverse effects of ephedrine, but one study reported that a dose of more than 48 mg/day was not tolerated in one person (<a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>, <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a>, and <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a>). Surprisingly, pre‐existent tachycardia improved when ephedrine was given in the same person. One child died of unknown causes five days after glycine was added to ephedrine (<a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>). </p> </section> <section id="CD010028-sec-0082"> <h3 class="title" id="CD010028-sec-0082">Summary of main results</h3> <p>Our literature search did not identify any RCTs or quasi‐RCTs, but did identify a large number of non‐randomised studies that describe the effects of ephedrine in autoimmune MG and the CMSs. Some of the reports date to the first half of the 20th century, illustrating that ephedrine has been used to treat myasthenic symptoms for almost a hundred years. </p> <p>A wide range of doses was reported in these non‐randomised studies. People usually received a total oral dose of 50 to 200 mg/day (adults) or 0.5 to 3.0 mg/kg/day (children) divided over several doses, although some benefited from much smaller doses, for example 7.5 or 16 mg/day. Ephedrine was often used in combination with other drugs, such as AChEIs, neostigmine, or 3,4‐DAP. </p> <p>We had aimed to include only results from RCTs or quasi‐RCTs and describe the results of non‐randomised studies in the <a href="#CD010028-sec-0059">Discussion</a> if the results from RCTs or quasi‐RCTs had left any knowledge gaps. However, our search did not identify <i>any</i> RCTs or quasi‐RCTs and so we considered whether the results from the identified before‐and‐after studies could be evaluated according to the Cochrane Effective Practice and Organisation of Care (EPOC) guideline (<a href="./references#CD010028-bbs2-0041" title="EffectivePractice , Organisation of Care(EPOC) . EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services; 2013. Available at: epocoslo.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 1 November 2014). ">EPOC 2013</a>). This guideline describes which study designs, other than RCTs and non‐randomised controlled trials, should be considered in a review of the effectiveness of a healthcare intervention. However, we decided that the included before‐and‐after studies could not be evaluated according to the EPOC guideline, because a control group or multiple measurements before and after the intervention were lacking. We therefore decided not to give primacy to the results of any one type of non‐randomised study and summarised all non‐randomised evidence. However, a high risk of bias should be assumed for the non‐randomised studies presented here and no firm conclusions about the efficacy of ephedrine in autoimmune MG or CMSs can be drawn from this evidence. </p> <p>Nevertheless, many of the included reports describe favourable effects of ephedrine on myasthenic symptoms (<a href="#CD010028-tbl-0001">Table 1</a>). Only some of the studies reported no effects or adverse effects, which led to the discontinuation of ephedrine in some people. Adverse effects were most commonly experienced in the first days or weeks after starting treatment with ephedrine, or after a dose increase. The adverse effect reported most often was tachycardia, but sleep disturbances, anxiety, and epistaxis were also reported. Some people showed habituation to ephedrine, and one person experienced withdrawal symptoms. </p> </section> <section id="CD010028-sec-0083"> <h3 class="title" id="CD010028-sec-0083">Overall completeness and applicability of evidence</h3> <p>Despite the large number of non‐randomised studies described in this review, many gaps in our knowledge remain. We have already noted that the results from the non‐randomised studies should be interpreted with caution. In addition, we found a relatively large number of studies for some types of myasthenia (such as COLQ CMS and DOK7 CMS), while for others (such as autoimmune MG, AGRN CMS, or RAPSN CMS) only a small number of studies was available, or even only a single case report (e.g. LAMB2, fast‐channel CMS, slow‐channel CMS). Furthermore, it should be noted that selection for treatment with ephedrine may have been biased towards those who were likely to show a favourable response or who responded poorly to medications of first choice (confounding by indication). Because the studies were not prospective or controlled, information bias is also a risk. Publication bias may have occurred towards cases in which positive responses to ephedrine had been recorded, although the fact that the effectiveness of ephedrine was not the main topic of most studies makes it less likely that this occurred. For these various reasons, the results from non‐randomised studies should be interpreted with caution. </p> </section> <section id="CD010028-sec-0084"> <h3 class="title" id="CD010028-sec-0084">Quality of the evidence</h3> <p>The quality of the evidence was low: we did not identify any RCTs or quasi‐RCTs and all studies described in this review were non‐randomised. In addition, reporting in these studies was often poor. First, many studies did not fully report on characteristics such as dose, frequency, and duration of ephedrine treatment, co‐medication, and time points at which the effects of treatment were assessed. Secondly, recognised and validated outcome measures were rarely used, and outcomes were often described in imprecise and vague terms, which made comparisons across studies difficult. Finally, adverse effects were seldom included or adequately described. </p> </section> <section id="CD010028-sec-0085"> <h3 class="title" id="CD010028-sec-0085">Potential biases in the review process</h3> <p>We have attempted to minimise potential biases in the review process by having two review authors independently assess eligibility for inclusion (AZ and CV), by having two review authors (AZ and SW) conduct the data extraction independently, and by referring to a third review author (JV) to resolve any disagreements. Furthermore, to minimise language bias, we consulted native speakers during the data extraction process for publications in languages unfamiliar to the review authors. </p> </section> <section id="CD010028-sec-0086"> <h3 class="title" id="CD010028-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, no prior systematic reviews about the effects of ephedrine in MG, NMG or CMSs have been conducted. However, our literature search identified a number of narrative reviews which discuss the general treatment of CMS, and some of these included the use of ephedrine. Several recent reviews state that ephedrine may be beneficial in people with DOK7 (<a href="./references#CD010028-bbs2-0037" title="EngelAG . The therapy of congenital myasthenic syndromes. Neurotherapeutics2007;4(2):252‐7. ">Engel 2007</a>; <a href="./references#CD010028-bbs2-0039" title="EngelAG . Current status of the congenital myasthenic syndromes. Neuromuscular Disorders2012;22(2):99‐111. ">Engel 2012</a>; <a href="./references#CD010028-bbs2-0040" title="EngelAG . Congenital myasthenic syndromes in 2012. Current Neurology and Neuroscience Reports2012;12(1):92‐101. ">Engel 2012a</a>; <a href="./references#CD010028-bbs2-0075" title="LorenzoniPJ , ScolaRH , KayCSK , WerneckLC . Congenital myasthenic syndrome: a brief review. Pediatric Neurology2012;46(3):141‐8. ">Lorenzoni 2012</a>; <a href="./references#CD010028-bbs2-0096" title="PalaceJ , BeesonD . The congenital myasthenic syndromes. Journal of Neuroimmunology2008;201‐202:2‐5. ">Palace 2008</a>; <a href="./references#CD010028-bbs2-0109" title="ScharaU , LochmüllerH . Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics2008;5(4):542‐7. ">Schara 2008</a>), COLQ (<a href="./references#CD010028-bbs2-0037" title="EngelAG . The therapy of congenital myasthenic syndromes. Neurotherapeutics2007;4(2):252‐7. ">Engel 2007</a>; <a href="./references#CD010028-bbs2-0039" title="EngelAG . Current status of the congenital myasthenic syndromes. Neuromuscular Disorders2012;22(2):99‐111. ">Engel 2012</a>; <a href="./references#CD010028-bbs2-0040" title="EngelAG . Congenital myasthenic syndromes in 2012. Current Neurology and Neuroscience Reports2012;12(1):92‐101. ">Engel 2012a</a>; <a href="./references#CD010028-bbs2-0075" title="LorenzoniPJ , ScolaRH , KayCSK , WerneckLC . Congenital myasthenic syndrome: a brief review. Pediatric Neurology2012;46(3):141‐8. ">Lorenzoni 2012</a>; <a href="./references#CD010028-bbs2-0096" title="PalaceJ , BeesonD . The congenital myasthenic syndromes. Journal of Neuroimmunology2008;201‐202:2‐5. ">Palace 2008</a>; <a href="./references#CD010028-bbs2-0109" title="ScharaU , LochmüllerH . Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics2008;5(4):542‐7. ">Schara 2008</a>), LAMB2 (<a href="./references#CD010028-bbs2-0075" title="LorenzoniPJ , ScolaRH , KayCSK , WerneckLC . Congenital myasthenic syndrome: a brief review. Pediatric Neurology2012;46(3):141‐8. ">Lorenzoni 2012</a>), RAPSN (<a href="./references#CD010028-bbs2-0037" title="EngelAG . The therapy of congenital myasthenic syndromes. Neurotherapeutics2007;4(2):252‐7. ">Engel 2007</a>; <a href="./references#CD010028-bbs2-0039" title="EngelAG . Current status of the congenital myasthenic syndromes. Neuromuscular Disorders2012;22(2):99‐111. ">Engel 2012</a>; <a href="./references#CD010028-bbs2-0040" title="EngelAG . Congenital myasthenic syndromes in 2012. Current Neurology and Neuroscience Reports2012;12(1):92‐101. ">Engel 2012a</a>), AGRN (<a href="./references#CD010028-bbs2-0075" title="LorenzoniPJ , ScolaRH , KayCSK , WerneckLC . Congenital myasthenic syndrome: a brief review. Pediatric Neurology2012;46(3):141‐8. ">Lorenzoni 2012</a>), and slow‐channel CMS (<a href="./references#CD010028-bbs2-0096" title="PalaceJ , BeesonD . The congenital myasthenic syndromes. Journal of Neuroimmunology2008;201‐202:2‐5. ">Palace 2008</a>). Some of these reviews combine evidence available from the literature with the clinical expertise of the review authors. We have included in this review all relevant references that were referred to by the authors of these reviews. However, in the present review, we deemed this evidence to be of insufficient quality either to support or to discourage the use of ephedrine for these syndromes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010028-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/media/CDSR/CD010028/urn:x-wiley:14651858:media:CD010028:CD010028-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/media/CDSR/CD010028/image_t/tCD010028-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (a supplementary search shortly before publication resulted in 16 references, no RCTs or quasi‐RCTs and seven additional studies to be assessed for inclusion in the Discussion at the next update)." data-id="CD010028-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010028.pub2/media/CDSR/CD010028/image_n/nCD010028-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (a supplementary search shortly before publication resulted in 16 references, no RCTs or quasi‐RCTs and seven additional studies to be assessed for inclusion in the Discussion at the next update). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/media/CDSR/CD010028/image_n/nCD010028-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010028-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summaries of findings of non‐randomised studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of myasthenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Before‐after studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Case series</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Case reports</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of people in review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ephedrine dose (orally, unless stated otherwise)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Autoimmune</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AChR MG</p> <p>(<a href="./references#CD010028-bbs2-0055" title="HashimotoA , HanadaM , OkadaS , AokiN . A case report of myasthenia gravis associated with Hashimoto's thyroiditis. Folia Psychiatrica et Neurologica Japonica1981;35(4):521‐5. ">Hashimoto 1981</a>; <a href="./references#CD010028-bbs2-0077" title="MacdonaldAM , KeenRI , PughND . Myasthenia gravis and atracurium: a case report. British Journal of Anaesthesia1984;56(6):651‐4. ">Macdonald 1984</a>; <a href="./references#CD010028-bbs2-0082" title="McAlpineJK , ThomsonJE . Myasthenia gravis and Schmidt syndrome. Postgraduate Medical Journal1988;64(756):787‐8. ">McAlpine 1988</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 to 40 mg 4 times daily</p> <p>or 4 mg I.V. Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in muscle strength in 3 people. Adverse effects reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MuSK MG</p> <p>(<a href="./references#CD010028-bbs2-0034" title="EhlerE , LattaJ . Myasthenia with positive anti‐MuSK‐positive antibodies in a young man: a case report [Myastenie s pozitivními anti‐MuSK protilátkami u mladého muže: kazuistika]. Ceska a Slovenska Neurologie a Neurochirurgie2008;71(1):101‐4. ">Ehler 2008</a>; <a href="./references#CD010028-bbs2-0053" title="HaranM , SchattnerA , MateA , StarobinD , HaranG , ShtalridM . Can a rare form of myasthenia gravis shed additional light on disease mechanisms?. Clinical Neurology and Neurosurgery2013;115(5):562‐6. ">Haran 2013</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to 50 mg 3 times daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in symptoms in 2 people. Adverse effects reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neonatal myasthenia gravis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Congenital myasthenic syndromes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Presynaptic</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHAT</p> <p>(<a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a> and <a href="./references#CD010028-bbs2-0105" title="RobbSA , MuntoniF , SimondsAK . Respiratory management of congenital myasthenic syndromes in childhood: Workshop 8th December 2009, UCL Institute of Neurology, London, UK. Neuromuscular Disorders2010;20(12):833‐8. ">Robb 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in symptoms in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Presynaptic other</p> <p>(<a href="./references#CD010028-bbs2-0036" title="EngelAG , OhnoK , SineSM . Congenital myasthenic syndromes: progress over the past decade. Muscle &amp; Nerve2003;27(1):4‐25. ">Engel 2003</a> and <a href="./references#CD010028-bbs2-0078" title="MaselliRA , KongDZ , BoweCM , McDonaldCM , EllisWG , AgiusMA , et al. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology2001;57(2):279‐89. ">Maselli 2001</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvement in muscle strength and fatigue in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Synaptic</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AGRN</p> <p>(<a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0060" title="HuzéC , BauchéS , RichardP , ChevessierF , GoillotE , GaudonK , et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. American Journal of Human Genetics2009;85(2):155‐67. ">Huzé 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg/day</p> <p>or 2 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in muscle strength, endurance and well‐being in 2 people. No change in 1 person. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COLQ</p> <p>(<a href="./references#CD010028-bbs2-0003" title="AdamovičováM , FabriciováK , JakubíkováM , PříhodováI , KlementP , SýkoraP , et al. Congenital myasthenia as a cause of respiratory failure in two infants and a toddler: case reports [Kongenitální myastenie jako příčina respiračního selhání u dvou kojenců a batolete: kazuistiky]. Ceska a Slovenska Neurologie a Neurochirurgie2012;75(6):757‐62. ">Adamovičová 2012</a>; <a href="./references#CD010028-bbs2-0010" title="Bestue‐CardielM , Sáenz de Cabezón‐AlvarezA , Capablo‐LiesaJL , López‐PisónJ , Peña‐SeguraJL , Martin‐MartinezJ , et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology2005;65(1):144‐6. ">Bestue‐Cardiel 2005</a>, <a href="./references#CD010028-bbs2-0011" title="BestuéM , CapabloJL , Sáenz de CabezónA , López‐PisónJ , BenaventeI , LarrodéP , et al. [Mutación Y430S en un grupo de cinco pacientes con miastenia congénita por déficit de acetilcolinesterasa (AChE). Es una mutación fundacional hispánica?]. Comunicacones Orales de la Sociedad Española de Neurología2006;21(9):455‐550. ">Bestué 2006</a>, <a href="./references#CD010028-bbs2-0013" title="BrengmanJ , Capablo‐LiesaJL , Bestue‐CardielM , López‐PisónJ , Peña‐SeguraJL , Benavente‐AguilarI , et al. Ephedrine treatment of seven patients with congenital endplate (EP) acetylcholinesterase (AChE) deficiency. Neuromuscular Disorders2006;16(Suppl 1):S129. ">Brengman 2006</a> and <a href="./references#CD010028-bbs2-0038" title="EngelAG , ShenXM , SelcenD , SineSM . Further observations in congenital myasthenic syndromes. Annals of the New York Academy of Sciences2008;1132:104‐13. ">Engel 2008</a>; </p> <p><a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0022" title="ChillingworthA , HicksE , BeesonD , RobbS , PeakeD . Variable response to ephedrine in COLQ congenital myasthenic syndrome despite phenotypic and genotypic homogeneity within the same family. Developmental Medicine &amp; Child Neurology2009;51(Suppl 1):24. ">Chillingworth 2009</a>; <a href="./references#CD010028-bbs2-0033" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">Edvardson 2007</a> and <a href="./references#CD010028-bbs2-0001" title="EdvardsonS , ShapirahY . Treatment of congenital myasthenia with ephedrine: a case report. European Journal of Paediatric Neurology2007;11(Suppl 1):38. ">NCT00541216</a>; <a href="./references#CD010028-bbs2-0050" title="GuvenA , DemirciM , AnlarB . Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatric Neurology2012;46(4):253‐6. ">Guven 2012</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0086" title="MihaylovaV , MüllerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Phenotypical spectrum of congenital myasthenic syndrome caused by mutations in COLQ gene. Journal of Neurology2008;255(Suppl 2):185. ">Mihaylova 2008a</a>, <a href="./references#CD010028-bbs2-0087" title="MihaylovaV , MullerJ , VilchezJ , SalihM , KabirajM , D'AmicoA , et al. Clinical and molecular genetic findings in 22 COLQ‐mutant CMS patients. Neurology2008;70(11):A426. ">Mihaylova 2008b</a>, <a href="./references#CD010028-bbs2-0088" title="MihaylovaV , MüllerJS , VilchezJJ , SalihMA , KabirajMM , D'AmicoA , et al. Clinical and molecular genetic findings in COLQ‐mutant congenital myasthenic syndromes. Brain2008;131(Pt 3):747‐59. ">Mihaylova 2008c</a> and <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>; <a href="./references#CD010028-bbs2-0127" title="WargonI , RichardP , KuntzerT , SternbergD , NafissiS , GaudonK , et al. Long‐term follow‐up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscular Disorders2012;22(4):318‐24. ">Wargon 2012</a>, <a href="./references#CD010028-bbs2-0126" title="WargonI , RichardP , KuntzerT , NafissiS , GaudonK , SternbergD , et al. P5.17 Congenital Myasthenic Syndromes with COLQ mutations: long term follow‐up. Neuromuscular Disorders2011;21(9):728‐9. ">Wargon 2011</a> and <a href="./references#CD010028-bbs2-0007" title="BauduinH , ServaisL , RichardP , SternbergD , FournierE , LaforetP , et al. Pregnancy outcome in congenital myasthenic syndromes. Neuromuscular Disorders2011;21(9‐10):728. ">Bauduin 2011</a>; <a href="./references#CD010028-bbs2-0133" title="YeungWL , LamCW , NgPC . Intra‐familial variation in clinical manifestations and response to ephedrine in siblings with congenital myasthenic syndrome caused by novel COLQ mutations. Developmental Medicine &amp; Child Neurology2010;52(10):e243‐4. ">Yeung 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 to 200 mg/day (adults)</p> <p>or 0.5 to 5 mg/kg/day (children). Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in endurance, muscle strength or both in about half of 29 people. Possible improvements in quality of life and respiration. </p> <p>No change reported in 3 people. Adverse effects reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LAMB2</p> <p>(<a href="./references#CD010028-bbs2-0079" title="MaselliRA , NgJJ , AndersonJA , CagneyO , ArredondoJ , WilliamsC , et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. Journal of Medical Genetics2009;46(3):203‐8. ">Maselli 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Postsynaptic</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CHRNE</p> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; <a href="./references#CD010028-bbs2-0065" title="KhanA , HussainN , GosalakkalJA . Bulbar dysfunction: An early presentation of congenital myasthenic syndrome in three infants. Journal of Pediatric Neurosciences2011;6(2):124‐6. ">Khan 2011</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0073" title="LinzoainJ , Avila‐SmirnovD , EssidN , RubinzstajnR , BigueV , RenaultF , et al. Challenges in diagnosis and management of a patient with severe congenital myasthenic syndrome mutated in CHRNE. Neuromuscular Disorders2011;21(9):727‐8. ">Linzoain 2011</a>; <a href="./references#CD010028-bbs2-0081" title="MaselliRA , ArredondoJ , CagneyO , MozaffarT , SkinnerS , YousifS , et al. Congenital myasthenic syndrome associated with epidermolysis bullosa caused by homozygous mutations in PLEC1 and CHRNE. Clinical Genetics2011;80(5):444‐51. ">Maselli 2011</a>; <a href="./references#CD010028-bbs2-0094" title="NogajskiJH , KiernanMC , OuvrierRA , AndrewsPI . Congenital myasthenic syndromes. Journal of Clinical Neuroscience2009;16(1):1‐11. ">Nogajski 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 mg twice daily. Not reported in most.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in 9/14 people. No change in 4 people. Adverse effects suspected.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DOK7</p> <p>(<a href="./references#CD010028-bbs2-0004" title="AndersonJA , NgJJ , BoweC , McDonaldC , RichmanDP , WollmannRL , et al. Variable phenotypes associated with mutations in DOK7. Muscle &amp; Nerve2008;37(4):448‐56. ">Anderson 2008</a>; <a href="./references#CD010028-bbs2-0009" title="Ben AmmarA , PetitF , AlexandriN , GaudonK , BauchéS , RoucheA , et al. Phenotype genotype analysis in 15 patients presenting a congenital myasthenic syndrome due to mutations in DOK7. Journal of Neurology2010;257(5):754‐66. ">Ben Ammar 2010</a> and <a href="./references#CD010028-bbs2-0107" title="SarkozyA , LochmüllerH . Neuromuscular disorders and 2010: recent advances. Journal of Neurology2010;257(12):2117‐21. ">Sarkozy 2010</a>; <a href="./references#CD010028-bbs2-0015" title="BurkeG , AllenD , ArunachalamR , BeesonD , HammansS . A treatable muscle disease. Practical Neurology2009;9(4):233‐6. ">Burke 2009</a>; <a href="./references#CD010028-bbs2-0017" title="BurkeG , HiscockA , KleinA , NiksEH , MainM , ManzurAY , et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular disorders2013;23(2):170‐5. ">Burke 2013</a> and <a href="./references#CD010028-bbs2-0016" title="BurkeG , HiscockA , KleinA , NgJ , ManzurAY , DeVileC , et al. Salbutamol treatment in children with DOK7 congenital myasthenic syndrome. European Journal of Paediatric Neurology2011;15(Suppl 1):S20. ">Burke 2011</a>; <a href="./references#CD010028-bbs2-0027" title="Della MarinaA , AbichtA , ScharaU . Congenital myasthenic syndromes [Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie]. Nervenheilkunde2011;30(10):797‐804. ">Della Marina 2011</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0070" title="LashleyD , PalaceJ , JayawantS , RobbS , BeesonD . Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology2010;74(19):1517‐23. ">Lashley 2010</a>, <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>, <a href="./references#CD010028-bbs2-0023" title="CossinsJ , LashleyD , SpearmanH , MaxwellS , PalaceJ , RobbS , et al. Ephedrine treatment in DOK7 CMS and investigation of potential mechanisms. Neuromuscular Disorders2010;20(Suppl 1):S18. ">Cossins 2010</a> and <a href="./references#CD010028-bbs2-0069" title="LashleyD , BeesonD , JayawantS , PalaceJ . Ephedrine treatment results in profound functional improvements in DOK‐7 congenital myasthenia. Journal of Neurology, Neurosurgery &amp; Psychiatry2009;80(11):24. ">Lashley 2009</a>; <a href="./references#CD010028-bbs2-0095" title="PalaceJ , LashleyD , Newsom‐DavisJ , CossinsJ , MaxwellS , KennettR , et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain2007;130(Pt 6):1507‐15. ">Palace 2007</a> and <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>; <a href="./references#CD010028-bbs2-0110" title="ScharaU , BarišićN , DeschauerM , LindbergC , StraubV , Strigl‐PillN , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2009;19(12):828‐32. ">Schara 2009</a> and <a href="./references#CD010028-bbs2-0108" title="ScharaU , DeschauerM , WendtM , Strigl‐PillN , MüllerJS , AbichtA , et al. Therapeutic effects of ephedrine in congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2007;17(9‐10):818‐9. ">Schara 2007</a>; <a href="./references#CD010028-bbs2-0111" title="ScharaU , Della MarinaA , AbichtA . Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. Neuropediatrics2012;43(4):184‐93. ">Schara 2012</a>; <a href="./references#CD010028-bbs2-0114" title="SelcenD , MiloneM , ShenX‐M , HarperCM , StansAA , WiebenED , et al. Dok‐7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Annals of Neurology2008;64(1):71‐87. ">Selcen 2008</a>; <a href="./references#CD010028-bbs2-0119" title="SrourM , BolducV , GuergueltchevaV , LochmüllerH , GendronD , ShevellMI , et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscular Disorders2010;20(7):453‐7. ">Srour 2010</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5 to 100 mg/day</p> <p>or 0.5 to 1.0 mg/kg/day (children). Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in endurance, muscle strength, quality of life, or unspecified improvements in majority of 40 people. No response in 4 people. Adverse effects reported in 10 people. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fast channel</p> <p>(<a href="./references#CD010028-bbs2-0097" title="PalaceJ , LashleyD , BaileyS , JayawantS , CarrA , McConvilleJ , et al. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscular Disorders2012;22(2):112‐7. ">Palace 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possibly no effect in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limb‐girdle</p> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0118" title="SlaterCR , FawcettPRW , WallsTJ , LyonsPR , BaileySJ , BeesonD , et al. Pre‐ and post‐synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb‐girdle myasthenia'. Brain2006;129(8):2061‐76. ">Slater 2006</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in all 5 people.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MuSK</p> <p>(<a href="./references#CD010028-bbs2-0080" title="MaselliRA , ArredondoJ , CagneyÓ , NgJJ , AndersonJA , WilliamsC , et al. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK‐Dok‐7 interaction. Human Molecular Genetics2010;19(12):2370‐9. ">Maselli 2010</a>; <a href="./references#CD010028-bbs2-0089" title="MihaylovaV , SalihMAM , MukhtarMM , AbuzeidHA , El‐SadigSM , von derHagenM , et al. Refinement of the clinical phenotype in MUSK‐related congenital myasthenic syndromes. Neurology2009;73(22):1926‐28. ">Mihaylova 2009</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response in 1 person. Not tolerated in the other person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RAPSN</p> <p>(<a href="./references#CD010028-bbs2-0005" title="BanwellBL , OhnoK , SiebJP , EngelAG . Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4‐diaminopyridine. Neuromuscular Disorders2004;14(3):202‐7. ">Banwell 2004</a>; <a href="./references#CD010028-bbs2-0014" title="BurkeG , CossinsJ , MaxwellS , RobbS , NicolleM , VincentA , et al. Distinct phenotypes of congenital acetylcholine receptor deficiency. Neuromuscular Disorders2004;14(6):356‐64. ">Burke 2004</a>; <a href="./references#CD010028-bbs2-0020" title="ChaouchA , BeesonD , HantaïD , LochmüllerH . 186th ENMC international workshop: congenital myasthenic syndromes 24‐26 June 2011, Naarden, The Netherlands. Neuromuscular Disorders2012;22(6):566‐76. ">Chaouch 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in all 4 people.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow channel</p> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible slight improvement in 1 person.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i>Not genetically characterised CMS</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010028-bbs2-0008" title="BeesonD , HantaïD , LochmüllerH , EngelAG . 126th International workshop: congenital myasthenic syndromes, 24‐26 September 2004, Naarden, The Netherlands. Neuromuscular Disorders2005;15(7):498‐512. ">Beeson 2005</a>; <a href="./references#CD010028-bbs2-0046" title="FeliceK , RelvaG . Ephedrine in the treatment of congenital myasthenic syndrome. Muscle &amp; Nerve1996; Vol. 19, issue 6:799‐800. ">Felice 1996</a>; <a href="./references#CD010028-bbs2-0066" title="KinaliM , BeesonD , PittMC , JungbluthH , SimondsAK , AloysiusA , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. Journal of Neuroimmunology2008;201‐202:6‐12. ">Kinali 2008</a>; <a href="./references#CD010028-bbs2-0120" title="TerblancheN , MaxwellC , KeunenJ , CarvalhoJC . Obstetric and anesthetic management of severe congenital myasthenia syndrome. Anesthesia and Analgesia2008;107(4):1313‐5. ">Terblanche 2008</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 ‐ 50 mg oral,</p> <p>or 25 mg twice daily oral,</p> <p>or 25 mg I.M. Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No objective improvements in</p> <p>forced vital capacity, muscle strength, or RNS/CMAP decrement. Possible subjective improvements in strength. Adverse effects reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Unknown form of myasthenia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(<a href="./references#CD010028-bbs2-0019" title="Chan‐LuiWY , LeungNK , LauTTY . Myasthenia gravis in Chinese children. Developmental Medicine &amp; Child Neurology1984;26(6):717‐24. ">Chan‐Lui 1984</a>; <a href="./references#CD010028-bbs2-0025" title="DalkaraT , KansuT , KayaalpO , ZileliT . Pupillary dysfunction in myasthenia gravis: possible involvement of ciliary ganglion. Hacettepe Medical Journal1988;21(4):269‐74. ">Dalkara 1988</a>; <a href="./references#CD010028-bbs2-0031" title="EdgeworthH . A report of progress on the use of ephedrine in a case of myasthenia gravis. Journal of the American Medical Association1930;94(15):1136. ">Edgeworth 1930</a>, <a href="./references#CD010028-bbs2-0032" title="EdgeworthH . The effect of ephedrine in the treatment of myasthenia gravis: second report. Journal of the American Medical Association1933;100(18):1401. ">Edgeworth 1933</a> and <a href="./references#CD010028-bbs2-0012" title="BoothbyWM . Myasthenia gravis: the effect of treatment with glycine and ephedrine; third report. Archives of Internal Medicine1934;53(1):39‐45. ">Boothby 1934</a>; <a href="./references#CD010028-bbs2-0092" title="NelsonWE . Myasthenia gravis in a child: observations on the effect of ephedrine therapy. Journal of Pediatrics1935;7(2):231‐7. ">Nelson 1935</a>; <a href="./references#CD010028-bbs2-0099" title="PattenBM , HartA , LovelaceR . Multiple sclerosis associated with defects in neuromuscular transmission. Journal of Neurology, Neurosurgery, &amp; Psychiatry1972;35(3):385‐94. ">Patten 1972</a>; <a href="./references#CD010028-bbs2-0100" title="PearceJMS . Mary Broadfoot Walker (1888‐1974): a historic discovery in myasthenia gravis. European Neurology2005;53(1):51‐3. ">Pearce 2005</a>, <a href="./references#CD010028-bbs2-0061" title="JohnstonJD . Special section on myasthenia: the contributions of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. Journal of the History of the Neurosciences: Basic and Clinical Perspectives2005;14(2):121‐37. ">Johnston 2005</a>, <a href="./references#CD010028-bbs2-0124" title="WalkerMB . Treatment of myasthenia gravis with physostigmine. Lancet1934;223(5779):1200‐1. ">Walker 1934</a> and <a href="./references#CD010028-bbs2-0125" title="WalkerMB . A contribution to the study of myasthenia gravis [MD thesis]. Edinburgh, UK: University of Edinburgh, 1935. ">Walker 1935</a>; <a href="./references#CD010028-bbs2-0113" title="SchwarzH . Urecholine in myasthenia gravis. Canadian Medical Association Journal1955;72(5):346‐51. ">Schwarz 1955</a>; <a href="./references#CD010028-bbs2-0117" title="SimpsonJF , WesterbergMR , MageeKR . Myasthenia gravis: an analysis of 295 cases. Acta Neurologica Scandinavica1966;42 Suppl 23:1‐27. ">Simpson 1966</a>; <a href="./references#CD010028-bbs2-0122" title="VietsH , SchwabR . The diagnosis and treatment of myasthenia gravis: with special reference to the use of prostigmine. Journal of the American Medical Association1939;113(7):559‐63. ">Viets 1939</a>; <a href="./references#CD010028-bbs2-0128" title="WilsonA , StonerHB . Prostigmin and ephedrine in myasthenia gravis. Lancet1944;243(6292):429‐31. ">Wilson 1944</a>; <a href="./references#CD010028-bbs2-0132" title="YahrMD , DavisTK . Myasthenia gravis ‐ its occurrence in a seven‐year‐old female child. Journal of Pediatrics1944;25(3):218‐25. ">Yahr 1944</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 ‐ 96 mg oral,</p> <p>or &lt; 64 mg S.C.,</p> <p>or 3% eye drop</p> <p>solution. Not reported in some.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Possible improvements in a majority of people. No response in a minority. Adverse effects reported. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AChR: acetylcholine receptor; CMAP: compound muscle action potential; CMS: congenital myasthenic syndrome; I.M.: intramuscular; I.V.: intravenous; MG: myasthenia gravis; MuSK: muscle specific tyrosine kinase; n/a: not applicable; RNS: repetitive nerve stimulation; S.C.: subcutaneous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summaries of findings of non‐randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010028.pub2/full#CD010028-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010028.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010028-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010028-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD010028-note-0001">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD010028-note-0003">한국어</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010028\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010028\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010028\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010028\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010028\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010028.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010028.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010028.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010028.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010028.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724407092"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010028.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724407096"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010028.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e620edc27f3fd',t:'MTc0MDcyNDQwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 